Pyrrolobenzodiazepines

专利摘要:

公开号:AU2003282251A1
申请号:U2003282251
申请日:2003-11-14
公开日:2004-06-03
发明作者:Philip Wilson Howard；David Edwin Thurston
申请人:ADC Products UK Ltd；
IPC主号:A61K31-551

专利说明:
WO 2004/043963 PCT/GB2003/004963 PYRROLOBENZODIAZEPINES The present invention relates to pyrrolobenzodiazepines (PBDs), and in particular pyrrolobenzodiazepines having a C2-C3 double 5 bond, an aryl group at the C2 position, and particular substituents on that C2 aryl group. Background to the invention Some pyrrolobenzodiazepines (PBDs) have the ability to recognise 10 and bond to specific sequences of DNA; the preferred sequence is PuGPu. The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, et al., J. Am. Chem. Soc., 87, 5793-5795 (1965); Leimgruber, et al., J. Am. Chem. Soc., 87, 5791-5793 (1965)). Since then, a number of naturally occurring 15 PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, et al., Chem. Rev. 1994, 433-465 (1994)). Family members include abbeymycin (Hochlowski, et al., J. Antibiotics, 40, 145-148 (1987)), chicamycin (Konishi, et al., J. Antibiotics, 37, 200-206 (1984)), 20 DC-81 (Japanese Patent 58-180 487; Thurston, et al., Chem. Brit., 26, 767-772 (1990); Bose, et al., Tetrahedron, 48, 751-758 (1992)), mazethramycin (Kuminoto, et al., J. Antibiotics, 33, 665-667 (1980)), neothramycins A and B (Takeuchi, et al., J. Antibiotics, 29, 93-96 (1976)), porothramycin (Tsunakawa, et al., 25 J. Antibiotics, 41, 1366-1373 (1988)), prothracarcin (Shimizu, et al, J. Antibiotics, 29, 2492-2503 (1982); Langley and Thurston, J. Org. Chem., 52, 91-97 (1987)), sibanomicin (DC-102) (Hara, et al., J. Antibiotics, 41, 702-704 (1988); Itoh, et al., J. Antibiotics, 41, 1281-1284 (1988)), sibiromycin (Leber, et al., 30 J. Am. Chem. Soc., 110, 2992-2993 (1988)) and tomamycin (Arima, et al., J. Antibiotics, 25, 437-444 (1972)). PBDs are of the general structure: WO 2004/043963 PCT/GB2003/004963 2 10 9H 8 ~ A B 1a 1 6 0 3 They differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is 5 either an imine (N=C), a carbinolamine(NH-CH(OH)), or a carbinolamine methyl ether (NH-CH(OMe)) at the N10-C11 position which is the electrophilic centre responsible for. alkylating DNA. All of the known natural products have an (S)-configuration at the chiral C11a position which provides them with a right-handed 10 twist when viewed from the C ring towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In Antibiotics 111. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, Acc. Chem. 15 Res., 19, 230-237 (1986)). Their ability to form an adduct in the minor groove, enables them to interfere with DNA processing, hence their use as antitumour agents. The present inventors have previously disclosed, in WO 00/12508, 20 that the following compounds, amongst many other, are cytotoxic: MeO N_ H MeO N_ H MeO N MeO N OMe More recently, in Cooper. N., et al., Chem. Commun., 16, 1764 1765 (2002), the following compound was also disclosed as being 25 cytotoxic alongside the compounds shown above.
WO 2004/043963 PCT/GB2003/004963 3 MeO N- H
I
MeO N 0 Me Disclosure of the invention The present inventors have now discovered that a certain class of 5 these compounds exhibit surprising activity against cancer cell lines, compared to the known compounds discussed above. Therefore, a first aspect of the present invention is a compound of formula (I):
R
9 R) N_ H
R
7 _ N6r R 2 10 R 0 and salts, solvates, chemically protected forms, and prodrugs thereof, wherein: 6 79 R , R and R9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR', nitro, Me 3 Sn and halo; 15 where R and R' are independently selected from optionally substituted C 1 7 alkyl, C 3
-
20 heterocyclyl and CS-20 aryl groups; R8 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR', nitro, Me 3 Sn and halo, or the compound is a dimer with each monomer being of formula (I), where the R 8 groups of each monomers form together 20 a dimer bridge having the formula -X-R"-X- linking the monomers, where R" is a C3 1 2 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. 0, S, NH, and/or aromatic rings, e.g. benzene or pyridine, and each X is independently selected from 0, S, or NH; 25 or any pair of adjacent groups from R 6 to R 9 together form a group
-O-(CH
2 )p-O-, where p is 1 or 2; and R2 is selected from: (i) an optionally substituted napthyl group; (ii) an optionally substituted thiophenyl or furanyl group; and 30 WO 2004/043963 PCT/GB2003/004963 4 (iii) a phenyl group substituted by: (a) one or more chloro or fluoro groups; (b) an ethyl or propyl group; (c) a 4-t-butyl group; 5 (d) a 2-methyl group; (e) two methyl groups in the 2- and 6- positions. A second aspect of the present invention is the use of a compound of the first aspect of the invention in a method of therapy. 10 A third aspect of the present invention is a pharmaceutical composition containing a compound of the first aspect of the invention, and a pharmaceutically acceptable carrier or diluent. 15 A fourth aspect of the present invention provides the use of a compound of the first aspect of the invention in the manufacture of a medicament for treating a proliferative disease. One of ordinary skill in the art is readily able to determine 20 whether or not a candidate compound treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below. 25 The term "proliferative disease" pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo. 30 Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g. histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel 35 cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, WO 2004/043963 PCT/GB2003/004963 5 osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. 5 Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin. 10 Substituents The phrase "optionally substituted" as used herein, pertains to a parent group which may be unsubstituted or which may be substituted. 15 Unless otherwise specified, the term "substituted" as used herein, pertains to a parent group which bears one or more substitutents. The term "substituent" is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent 20 group. A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known. Examples of substituents are described in more detail below. 25
C-
7 alkyl: The term "Cm, alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 7 carbon atoms, which may be aliphatic or alicyclic, and which may be 30 saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below. Examples of saturated alkyl groups include, but are not limited 35 to, methyl (C 1 ), ethyl (C 2 ), propyl (C 3 ), butyl (C 4 ), pentyl (CS), hexyl (C 6 ) and heptyl (C).
WO 2004/043963 PCT/GB2003/004963 6 Examples of saturated linear alkyl groups include, but are not limited to, methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (amyl) (C 5 ), n-hexyl (C 6 ) and n-heptyl (C 7 ) 5 Examples of saturated branched alkyl groups include iso-propyl
(C
3 ), iso-butyl (C 4 ), sec-butyl (C 4 ), tert-butyl (C 4 ), iso-pentyl (C), and neo-pentyl (Cs).
C
2
.
7 Alkenyl: The term "C 2 - alkenyl" as used herein, pertains to 10 an alkyl group having one or more carbon-carbon double bonds. Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH 2 ), 1-propenyl (-CH=CH-CH 3 ), 2-propenyl (allyl, -CH-CH=CH 2 ), isopropenyl (1-methylvinyl, 15 -C(CH 3
)=CH
2 ), butenyl (C 4 ), pentenyl (C 5 ), and hexenyl (C).
C
2
-
7 alkynyl: The term "C 2 -7 alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds. 20 Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C=CH) and 2-propynyl (propargyl, CH 2 -C=CH). C3-1 cycloalkyl: The term "C3_7 cycloalkyl" as used herein, 25 pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms. 30 Examples of cycloalkyl groups include, but are not limited to, those derived from: saturated monocyclic hydrocarbon compounds: cyclopropane (C3), cyclobutane (C4), cyclopentane (C 5 ), 35 cyclohexane (C 6 ), cycloheptane (C), methylcyclopropane (C 4 ), dimethylcyclopropane (C 5 ), methylcyclobutane (C 5 ), dimethylcyclobutane (C6), methylcyclopentane (C 6
),
WO 2004/043963 PCT/GB2003/004963 7 dimethylcyclopentane (C 7 ) and methylcyclohexane (C 7 ); unsaturated monocyclic hydrocarbon compounds: cyclopropene (C 3 ), cyclobutene (C 4 ), cyclopentene (C 5 ), cyclohexene (C 6 ), methylcyclopropene (C 4 ), dimethylcyclopropene 5 (C 5 ), methylcyclobutene (C 5 ), dimethylcyclobutene (C 6 ), methylcyclopentene (C 6 ), dimethylcyclopentene (C 7 ) and methylcyclohexene (C 7 ); and saturated polycyclic hydrocarbon compounds: norcarane (C 7 ), norpinane (C 7 ), norbornane (C 7 ) 10
C
32 0 heterocyclyl: The term "C 3
-
20 heterocyclyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring 15 heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms. In this context, the prefixes (e.g. C 3
-
20 , C 3
-
7 , C 5
-
6 , etc.) denote the number of ring atoms, or range of number of ring atoms, 20 whether carbon atoms or heteroatoms. For example, the term
"C
5
-
6 heterocyclyl", as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms. Examples of monocyclic heterocyclyl groups include, but are not 25 limited to, those derived from: Ni: aziridine (C 3 ), azetidine (C 4 ), pyrrolidine (tetrahydropyrrole) (C), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C 5 ), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C 5 ), piperidine (C 6 ), dihydropyridine (C 6 ), 30 tetrahydropyridine (C 6 ), azepine (C 7 ); 01: oxirane (C 3 ), oxetane (C 4 ), oxolane (tetrahydrofuran) (C 5 ), oxole (dihydrofuran) (C 5 ), oxane (tetrahydropyran) (C 6 ), dihydropyran (C 6 ), pyran (C 6 ), oxepin (C 7 ); Si: thiirane (C 3 ), thietane (C 4 ), thiolane (tetrahydrothiophene) 35 (C 5 ), thiane (tetrahydrothiopyran) (C 6 ), thiepane (C 7 ); 02: dioxolane (Cs), dioxane (C 6 ), and dioxepane (C 7 ); 03: trioxane (C 6
);
WO 2004/043963 PCT/GB2003/004963 8
N
2 : imidazolidine (C 5 ), pyrazolidine (diazolidine) (C 5 ), imidazoline (Cs), pyrazoline (dihydropyrazole) (Cs), piperazine (Ce);
N
1 0 1 : tetrahydrooxazole (Cs), dihydrooxazole (C 5 ), 5 tetrahydroisoxazole (C_), dihydroisoxazole (C5), morpholine (C), tetrahydrooxazine (CE), dihydrooxazine (C 6 ), oxazine (C 6 );
N
1 5 1 : thiazoline (C 5 ), thiazolidine (C), thiomorpholine (C 6 );
N
2
C
1 : oxadiazine (C6);
O
1 S1: oxathiole (C 5 ) and oxathiane (thioxane) (C 6 ); and, 10 NiO 1 S1: oxathiazine (C 6 ) Examples of substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C), such as arabinofuranose, lyxofuranose, 15 ribofuranose, and xylofuranse, and pyranoses (C), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.
C
5
-
20 aryl: The term "C 5
-
20 aryl", as used herein, pertains to a 20 monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms. Preferably, each ring has from 5 to 7 ring atoms. 25 In this context, the prefixes (e.g. C3-20, C57, C5-6, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "Cs-6 aryl" as used herein, pertains to an aryl group having 5 or 6 ring atoms. 30 The ring atoms may be all carbon atoms, as in "carboaryl groups". Examples of carboaryl groups include, but are not limited to, those derived from benzene (i.e. phenyl) (C), naphthalene (Cio), azulene (Cio), anthracene (C4), phenanthrene (C1 4 ), naphthacene 35 (C 1 ), and pyrene (C 1 6
).
WO 2004/043963 PCT/GB2003/004963 9 Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g. 2
,
3 -dihydro-lH-indene)
(C
9 ), indene (C 9 ), isoindene (C 9 ), tetraline 5 (1,2,3,4-tetrahydronaphthalene (Cio), acenaphthene (C 1 2 ), fluorene
(C
1 3 ), phenalene (C 1 3 ), acephenanthrene (C 15 ), and aceanthrene
(C
16 ) Alternatively, the ring atoms may include one or more 10 heteroatoms, as in "heteroaryl groups". Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:
N
1 : pyrrole (azole) (C 5 ), pyridine (azine) (C 6 ); 01: furan (oxole) (C 5 ); 15 Si: thiophene (thiole) (Cs);
N
1 0 1 : oxazole (C 5 ), isoxazole (C 5 ), isoxazine (C 6 );
N
2 0 1 : oxadiazole (furazan) (C 5 );
N
3 0 1 : oxatriazole (C 5 ); NiSi: thiazole (C 5 ), isothiazole (C 5 ); 20 N 2 : imidazole (1,3-diazole) (C 5 ), pyrazole (1,2-diazole) (C 5 ), pyridazine (1,2-diazine) (C 6 ), pyrimidine (1,3-diazine) (C 6 ) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C 6 );
N
3 : triazole (C 5 ), triazine (C); and,
N
4 : tetrazole
(C
5 ). 25 Examples of heteroaryl which comprise fused rings, include, but are not limited to:
C
9 (with 2 fused rings) derived from benzofuran (01), isobenzofuran (01), indole (N 1 ), isoindole (NI), indolizine (NI), 30 indoline (N 1 ), isoindoline (Ni), purine (N 4 ) (e.g., adenine, guanine), benzimidazole (N 2 ), indazole (N 2 ), benzoxazole (N 1 0 1 ), benzisoxazole (N 1 0 1 ), benzodioxole (02), benzofurazan (N20 1 ), benzotriazole (N 3 ), benzothiofuran (Si), benzothiazole (N 1 S,), benzothiadiazole
(N
2 S); 35 CIO (with 2 fused rings) derived from chromene (01), isochromene (01), chroman (01), isochroman (01), benzodioxan (02), quinoline (N 1 ), isoquinoline (N 1 ), quinolizine (NI), benzoxazine WO 2004/043963 PCT/GB2003/004963 10
(N
1 0 1 ), benzodiazine (N 2 ), pyridopyridine
(N
2 ), quinoxaline (N 2 ), quinazoline (N 2 ), cinnoline (N 2 ), phthalazine (N 2 ), naphthyridine
(N
2 ) , pteridine
(N
4 ) ;
C
11 (with 2 fused rings) derived from benzodiazepine
(N
2 ); 5 C 13 (with 3 fused rings) derived from carbazole (N 1 ), dibenzofuran (01), dibenzothiophene (S1), carboline (N 2 ), perimidine (N 2 ), pyridoindole (N 2 ); and,
C
1 4 (with 3 fused rings) derived from acridine (NI), xanthene (01), thioxanthene (Si), oxanthrene (02), phenoxathiin (0 1
S
1 ), 10 phenazine (N 2 ), phenoxazine (N 1 0 1 ), phenothiazine (NiSi), thianthrene (S2), phenanthridine (Ni), phenanthroline (N 2 ), phenazine
(N
2 ) The above groups, whether alone or part of another substituent, 15 may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below. Halo: -F, -Cl, -Br, and -I. 20 Hydroxy: -OH. Ether: -OR, wherein R is an ether substituent, for example, a Ci_ alkyl group (also referred to as a Ci_ alkoxy group, discussed 25 below), a C 3 20 heterocyclyl group (also referred to as a C 3
-
20 heterocyclyloxy group), or a C 5
-
20 aryl group (also referred to as a C 5
-
20 aryloxy group), preferably a C 1
-
7 alkyl group. Alkoxy: -OR, wherein R is an alkyl group, for example, a Ci_ alkyl 30 group. Examples of C 1
-
7 alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy). 35 Acetal: -CH(OR') (OR 2 ), wherein R' and R 2 are independently acetal substituents, for example, a C 1
-
7 alkyl group, a C 3
-
20 heterocyclyl group, or a C5- 20 aryl group, preferably a C 1
-
7 alkyl group, or, in WO 2004/043963 PCT/GB2003/004963 11 the case of a "cyclic" acetal group, R1 and R 2 , taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups 5 include, but are not limited to, -CH(OMe) 2 , -CH(OEt) 2 , and -CH(OMe) (OEt). Hemiacetal: -CH (OH) (OR 1 ), wherein R' is a hemiacetal substituent, for example, a C7 alkyl group, a C3- 20 heterocyclyl group, or a 10 Cs- 2 0 aryl group, preferably a Cs- alkyl group. Examples of hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and -CH(OH)(OEt). Ketal: -CR(OR') (OR 2 ), where R1 and R 2 are as defined for acetals, 15 and R is a ketal substituent other than hydrogen, for example, a
C
1 7 alkyl group, a C3-20 heterocyclyl group, or a C5- 20 aryl group, preferably a C 1 7 alkyl group. Examples ketal groups include, but are not limited to, -C(Me) (OMe) 2 , -C(Me) (OEt) 2 , -C(Me) (OMe) (OEt), -C(Et) (OMe) 2 , -C(Et) (OEt) 2 , and -C(Et) (OMe) (OEt) 20 Hemiketal: -CR(OH) (OR'), where R 1 is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C17 alkyl group, a C320 heterocyclyl group, or a C5-20 aryl group, preferably a C1_ alkyl group. Examples of hemiacetal 25 groups include, but are not limited to, -C(Me)(OH) (OMe), C(Et) (OH) (OMe), -C(Me) (dH) (OEt), and -C(Et) (OH) (OEt). Oxo (keto, -one): =O. 30 Thione (thioketone): =S. Imino (imine): =NR, wherein R is an imino substituent, for example, hydrogen, C1_, alkyl group, a C320 heterocyclyl group, or a C5-20 aryl group, preferably hydrogen or a C1- alkyl group. 35 Examples of ester groups include, but are not limited to, =NH, =NMe, =NEt, and =NPh.
WO 2004/043963 PCT/GB2003/004963 12 Formyl (carbaldehyde, carboxaldehyde): -C(=O)H. Acyl (keto): -C(=O)R, wherein R is an acyl substituent, for example, a C 1 , alkyl group (also referred to as C,, alkylacyl or 5 CJ 7 alkanoyl), a C3- 20 heterocyclyl group (also referred to as C 3
-
20 heterocyclylacyl), or a C 5
-
2 0 aryl group (also referred to as C5- 2 0 arylacyl), preferably a C- 7 alkyl group. Examples of acyl groups include, but are not limited to, -C(=O)CH 3 (acetyl), -C(=O)CH 2
CH
3 (propionyl), -C(=O)C(CH 3
)
3 (t-butyryl), and -C(=O)Ph benzoyll, 10 phenone). Carboxy (carboxylic acid): -C(=O)OH. Thiocarboxy (thiocarboxylic acid): -C(=S)SH. 15 Thiolocarboxy (thiolocarboxylic acid): -C(=O)SH. Thionocarboxy (thionocarboxylic acid): -C(=S)OH. 20 Imidic acid: -C(=NH)OH. Hydroxamic acid: -C(=NOH)OH. Ester (carboxylate, carboxylic acid ester, oxycarbonyl): 25 -C(=O)OR, wherein R is an ester substituent, for example, a C-7 alkyl group, a C3- 2 0 heterocyclyl group, or a C 5
-
2 0 aryl group, preferably a C 1 , alkyl group. Examples of ester groups include, but are not limited to, -C(=O)OCH 3 , -C(=O)OCH 2
CH
3 , -C(=O)OC(CH 3
)
3 , and -C(=O)OPh. 30 Acyloxy (reverse ester): -OC(=O)R, wherein R is an acyloxy substituent, for example, a C 1
-
7 alkyl group, a C 3
-
20 heterocyclyl group, or a C5-20 aryl group, preferably a C 1 7 alkyl group. Examples of acyloxy groups include, but are not limited to, 35 -OC(=O)CH 3 (acetoxy.), -OC(=O)CH 2
CH
3 , -OC(=O)C(.CH 3
)
3 , -OC(=O)Ph, and -OC (=0) CH 2 Ph.
WO 2004/043963 PCT/GB2003/004963 13 Oxycarboyloxy: -OC(=O)OR, wherein R is an ester substituent, for example, a Cs- alkyl group, a C 3 20 heterocyclyl group, or a C5 20 aryl group, preferably a C1-7 alkyl group. Examples of ester groups include, but are not limited to, -OC(=O)OCH 3 , 5 -OC(=O)OCH 2
CH
3 , -OC(=O)OC(CH 3
)
3 , and -OC(=O)OPh. 12 12 Amino: -NR R , wherein R and R are independently amino substituents, for example, hydrogen, a C- 7 alkyl group (also referred to as Cs 7 alkylamino or di-C 1 7 alkylamino), a C 3
-
20 10 heterocyclyl group, or a C 5 20 aryl group, preferably H or a C 1
-
7 alkyl group, or, in the case of a "cyclic" amino group, R 1 and R 2 taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups may be primary (-NH 2 ), secondary (-NHR), or tertiary ( 15 NHRR 2), and in cationic form, may be quaternary (-*NR R) . Examples of amino groups include, but are not limited to, -NH 2 ,
-NHCH
3 , -NHC(CH3) 2 , -N(CH 3
)
2 , -N(CH 2
CH
3
)
2 , and -NHPh. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and 20 thiomorpholino. Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide):
-C(=O)NRR
2 , wherein R1 and R 2 are independently amino substituents, as defined for amino groups. Examples of amido 25 groups include, but are not limited to, -C(=O)NH 2 , -C(=0)NHCH 3 , -C(=O)N(CH3)2, -C(=O)NHCH2CH 3 , and -C(=0)N(CH 2
CH
3
)
2 , as well as amido groups in which R 1 and R 2 , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, 30 thiomorpholinocarbonyl, and piperazinocarbonyl. Thioamido (thiocarbamyl): -C(=S)NR R2, wherein R' and R2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, 35 -C(=S)NH 2 , -C(=S)NHCH 3 , -C(=S)N(CH 3
)
2 , and -C(=S)NHCH 2
CH
3
.
WO 2004/043963 PCT/GB2003/004963 14 Acylamido (acylamino) : -NR'C(=0)R 2 , wherein R' is an amide substituent, for example, hydrogen, a C 1 - alkyl group, a C 3
-
20 heterocyclyl group, or a C 5
-
20 aryl group, preferably hydrogen or a Ci- alkyl group, and R2 is an acyl substituent, for example, a C1-7 5 alkyl group, a C 3
-
2 0 heterocyclyl group, or a C 5
-
20 aryl group, preferably hydrogen or a Ci- alkyl group. Examples of acylamide groups include, but are not limited to, -NHC(=O)CH 3 , -NHC (=0) CH 2
CH
3 , and -NHC (=O) Ph. R 1 and R 2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, 10 and phthalimidyl: O N O SoN o N succinimidyl maleimidyl phthalimidyl Aminocarbonyloxy: -OC(=0)NRR 2 , wherein R' and R 2 are independently amino substituents, as defined for amino groups. Examples of 15 aminocarbonyloxy groups include, but are not limited to, OC(=0)NH 2 , -OC(=0)NHMe, -OC(=O)NMe 2 , and -OC(=0)NEtz. Ureido: -N(R )CONR2R3 wherein R2 and R3 are independently amino substituents, as defined for amino groups, and R 1 is a ureido 20 substituent, for example, hydrogen, a C1- 7 alkyl group, a C 3
-
2 0 heterocyclyl group, or a C5-20 aryl group, preferably hydrogen or a
C
1
-
7 alkyl group. Examples of ureido groups include, but are not limited to, -NHCONH 2 , -NHCONHMe, -NHCONHEt, -NHCONMe 2 , -NHCONEt 2 , -NMeCONH 2 , -NMeCONHMe, -NMeCONHEt, -NMeCONMe 2 , and -NMeCONEt 2 . 25 Guanidino: -NH-C(=NH)NH2 Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom, N'N 30
N
WO 2004/043963 PCT/GB2003/004963 15 Imino:-=NR, wherein R is an imino substituent, for example, for example, hydrogen, a C 1 7 alkyl group, a C3 20 heterocyclyl group, or a C 5
-
20 aryl group, preferably H or a Ci-7alkyl group. Examples of imino groups include, but are not limited to, =NH, =NMe, and 5 =NEt. Amidine (amidino): -C(=NR)NR 2 , wherein each R is an amidine substituent, for example, hydrogen, a Ci-7 alkyl group, a C3 20 heterocyclyl group, or a Cs- 20 aryl group, preferably H or a Ci_ 7 10 alkyl group. Examples of amidine groups include, but are not limited to, -C(=NH)NH 2 , -C(=NH)NMe 2 , and -C(=NMe)NMe 2 . Nitro:
-NO
2 15 Nitroso: -NO. Azido: -N 3 . Cyano (nitrile, carbonitrile): -CN. 20 Isocyano: -NC. Cyanato: -OCN. 25 Isocyanato: -NCO. Thiocyano (thiocyanato): -SCN. Isothiocyano (isothiocyanato): -NCS. 30 Sulfhydryl (thiol, mercapto): -SR. Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a C1.7 alkyl group (also referred to as a Ci_alkylthio 35 group), a C3- 20 heterocyclyl group, or a Cs- 20 aryl group, preferably a Ci_ alkyl group. Examples of C>_ 7 alkylthio groups include, but are not limited to, -SCH 3 and -SCH 2
CH
3
.
WO 2004/043963 PCT/GB2003/004963 16 Disulfide: -SS-R, wherein R is a disulfide substituent, for example, a CI, alkyl group, a C 3
-
20 heterocyclyl group, or a C 5
-
20 aryl group, preferably a C 1 -7 alkyl group (also referred to herein 5 as C 1 7 alkyl disulfide) . Examples of C 1 7 alkyl disulfide groups include, but are not limited to, -SSCH 3 and -SSCH 2
CH
3 . Sulfine (sulfinyl, sulfoxide): -S(=O)R, wherein R is a sulfine substituent, for example, a Ci 7 alkyl group, a C3 2 0 heterocyclyl 10 group, or a C5-20 aryl group, preferably a C> 7 alkyl group. Examples of sulfine groups include, but are not limited to,
-S(=O)CH
3 and -S(=O)CH 2
CH
3 . Sulfone (sulfonyl): -S(=D) 2 R, wherein R is a sulfone substituent, 15 for example, a C>-, alkyl group, a C3 20 heterocyclyl group, or a Cs- 20 aryl group, preferably a Ci alkyl group, including, for example, a fluorinated or perfluorinated C>, alkyl group. Examples of sulfone groups include, but are not limited to,
-S(=O)
2 CH3 (methanesulfonyl, mesyl), -S(=0) 2
CF
3 (triflyl), 20 -S(=O) 2
CH
2 CH3 (esyl), -S(=O) 2
C
4 Fq (nonaflyl) , -S(=O) 2
CH
2 CF3 (tresyl), -S(=0) 2
CH
2
CH
2
NH
2 (tauryl), -S(=0) 2 Ph (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen 25 1-ylsulfonate (dansyl). Sulfinic acid (sulfino): -S(=O)OH, -SO 2 H. Sulfonic acid (sulfo) : -S(=0) 2 H, -SO 3 H. 30 Sulfinate (sulfinic acid ester): -S(=O)OR; wherein R is a sulfinate substituent, for example, a C 1 , alkyl group, a C3- 20 heterocyclyl group, or a C 5
-
20 aryl group, preferably a C1.7 alkyl group. Examples of sulfinate groups include, but are not limited 35 to, -S(=O)OCH3 (methoxysulfinyl; methyl sulfinate) and
-S(=O)OCH
2
CH
3 (ethoxysulfinyl; ethyl sulfinate).
WO 2004/043963 PCT/GB2003/004963 17 Sulfonate (sulfonic acid ester): -S(=0) 2 0R, wherein R is a sulfonate substituent, for example, a C1-7 alkyl group, a C3- 20 heterocyclyl group, or a Cs-20 aryl group, preferably a C 1 - alkyl group. Examples of sulfonate groups include, but are not limited 5 to, -S(=0) 2 0CH 3 (methoxysulfonyl; methyl sulfonate) and -S(=0) 2 0CH 2
CH
3 (ethoxysulfonyl; ethyl sulfonate). Sulfinyloxy: -OS(=O)R, wherein R is a sulfinyloxy substituent, for example, a CI- alkyl group, a C 3
-
2 0 heterocyclyl group, or a 10 C 5
-
2 aryl group, preferably a CI- alkyl group. Examples of sulfinyloxy groups include, but are not limited to, -OS(=O)CH 3 and -OS (=O)CH 2
CH
3 Sulfonyloxy: -OS(=0) 2 R, wherein R is a sulfonyloxy substituent, 15 for example, a C1-7 alkyl group, a C 3
-
20 heterocyclyl group, or a
C
5
-
20 aryl group, preferably a C 1 7 alkyl group. Examples of sulfonyloxy groups include, but are not limited to, -OS(=0) 2
CH
3 (mesylate) and -OS(=O) 2
CH
2
CH
3 (esylate). 20 Sulfate: -OS(=0) 2 0R; wherein R is a sulfate substituent, for example, a C>.7 alkyl group, a C3- 20 heterocyclyl group, or a C5-20 aryl group, preferably a C17 alkyl group. Examples of sulfate groups include, but are not limited to, -OS(=0) 2 0CH 3 and -s0 (=0) 2 0CH 2
CH
3 . 25 Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): -S(=O)NR R , wherein R' and R 2 are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, -S(=O)NH 2 , -S(=O)NH(CH3), 30 -S(=O)N(CH 3
)
2 , -S(=0)NH(CH 2
CH
3 ), -S(=O)N(CH 2
CH
3
)
2 , and -S(=O)NHPh. Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide):
-S(=O)
2 NRR 2, wherein R and R2 are independently amino substituents, as defined for amino groups. Examples of 35 sulfonamide groups include, but are not limited to, -S(=0) 2
NH
2 , -S (=O) 2 NH (CH 3 ) , -S (=O) 2 N (CH 3 ) 2 , -S (=O) 2 NH (CH 2
CH
3 ) , -S (=) 2 N (CH 2
CH
3 ) 2 , and -S(=O) 2 NHPh.
WO 2004/043963 PCT/GB2003/004963 18 Sulfamino: -NR'S(=0) 2 0H, wherein R 1 is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, but are not limited to, -NHS(=0) 2 0H and -N(CH 3 )S(=0) 2 0H. 5 Sulfonamino: -NR'S(=0) 2 R, wherein R' is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C1- alkyl group, a C 3
-
20 heterocyclyl group, or a C5- 20 aryl group, preferably a Ci- alkyl group. Examples of sulfonamino 10 groups include, but are not limited to, -NHS(=0) 2
CH
3 and -N (CH 3 ) S (=0) 2
C
6
H
5 . Sulfinamino: -NR S(=0)R, wherein R1 is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for 15 example, a C1- 7 alkyl group, a C3- 20 heterocyclyl group, or a CS-20 aryl group, preferably a C 1 - alkyl group. Examples of sulfinamino groups include, but are not limited to, -NHS(=0)CH 3 and -N (CH 3 ) S (=0) C 6
H
5 . 20 Phosphino (phosphine): -PR 2 , wherein R is a phosphino substituent, for example, -H, a C 1 j- alkyl group, a C 3
-
20 heterocyclyl group, or a C 5
-
20 aryl group, preferably -H, a C 1 7 alkyl group, or a C 5
-
20 aryl group. Examples of phosphino groups include, but are not limited to, -PH 2 , -P (CH 3 ) 2 , -P (CH 2
CH
3 ) 2 , -P (t-Bu) 2 , and -P (Ph) 2 25 Phospho: -P(=0) 2 Phosphinyl (phosphine oxide): -P(=0)R 2 , wherein R is a phosphinyl substituent, for example, a C 1 - alkyl group, a C 3
-
20 heterocyclyl 30 group, or a C- 20 aryl group, preferably a CI- alkyl group or a C 5
-
20 aryl group. Examples of phosphinyl groups include, but are not limited to, -P(=0) (CH 3
)
2 , -P(=0) (CH 2
CH
3
)
2 , -P(=0) (t-Bu) 2 , and -P(=0) (Ph)2 35 Phosphonic acid (phosphono): -P(=0) (OH) 2
.
WO 2004/043963 PCT/GB2003/004963 19 Phosphonate (phosphono ester): -P(=O) (OR) 2 , where R is a phosphonate substituent, for example, -H, a CI- 7 alkyl group, a
C
3 2 0 heterocyclyl group, or a C5-2o aryl group, preferably -H, a C 1 -, alkyl group, or a C 5
-
20 aryl group. Examples of phosphonate groups 5 include, but are not limited to, -P(=O) (OCH 3
)
2 , -P(=O) (OCH 2 CH3) 2 , -P(=O) (0-t-Bu) 2 , and -P(=O) (OPh) 2 Phosphoric acid (phosphonooxy): -OP(=O) (OH) 2 . 10 Phosphate (phosphonooxy ester) : -OP(=0) (OR) 2 , where R is a phosphate substituent, for example, -H, a C1- 7 alkyl group, a C 3
-
20 heterocyclyl group, or a C 520 aryl group, preferably -H, a Ci alkyl group, or a C 5 -2o aryl group. Examples of phosphate groups include, but are not limited to, -OP(=O) (OCH3) 2 , -OP(=O) (OCH 2
CH
3
)
2 , 15 -OP(=O) (O-t-Bu) 2 , and -OP(=O) (OPh) 2 Phosphorous acid: -OP(OH) 2 . Phosphite: -OP(OR) 2 , where R is a phosphite substituent, for 20 example, -H, a C 1 - alkyl group, a C 3
-
20 heterocyclyl group, or a C5 20 aryl group, preferably -H, a C 1 - alkyl group, or a C5 20 aryl group. Examples of phosphite groups include, but are not limited to, -OP(OCH 3
)
2 , -OP(OCH 2
CH
3
)
2 , -OP(O-t-Bu) 2 , and -OP(OPh) 2 . 25 Phosphoramidite: -OP(OR')-NR2 2 , where R' and R 2 are phosphoramidite substituents, for example, -H, a (optionally substituted) Ci 7 alkyl group, a C3 20 heterocyclyl group, or a Cs-2o aryl group, preferably -H, a C 1
-
7 alkyl group, or a Cs-o aryl group. Examples of phosphoramidite groups include, but are not limited to, 30 -OP(OCH 2
CH
3 )-N(CH3)2, -OP(OCH 2
CH
3 )-N(i-Pr)2, and -OP(OCH 2
CH
2 CN)-N(i Pr) 2. Phosphoramidate: -OP(=O) (OR')-NR 2 2 , where R1 and R 2 are phosphoramidate substituents, for example, -H, a (optionally 35 substituted) C 1 -, alkyl group, a C 3
-
20 heterocyclyl group, or a C5- 20 aryl group, preferably -H, a C 1 -7 alkyl group, or a Cs- 20 aryl group. Examples of phosphoramidate groups include, but are not WO 2004/043963 PCT/GB2003/004963 20 limited to, -OP (=0) (OCH 2
CH
3 ) -N (CH 3 ) 2, -OP (=0) (OCH 2
CH
3 ) -N (i-Pr) 2, and -OP(=0) (OCH 2
CH
2 CN)-N(i-Pr) 2 . Alkylene 5 C 3 1 2 alkylene: The term "C 3 1 2 alkylene", as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 3 to 12 carbon atoms (unless otherwise specified), which may be 10 aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated. Thus, the term "alkylene" includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below. 15 Examples of linear saturated C3-12 alkylene groups include, but are not limited to, -(CH 2 ),- where n is an integer from 3 to 12, for example, -CH 2
CH
2
CH
2 - (propylene), -CH 2
CH
2
CH
2
CH
2 - (butylene),
-CH
2
CH
2
CH
2
CH
2
CH
2 - (pentylene) and -CH 2
CH
2
CH
2
CH
2
CH
2
CH
2
CH
2 - (heptylene). 20 Examples of branched saturated C3 12 alkylene groups include, but are not limited to, -CH(CH 3
)CH
2 -, -CH(CH 3
)CH
2
CH
2 -,
-CH(CH
3
)CH
2
CH
2
CH
2 -, -CH 2
CH(CH
3
)CH
2 -, -CH 2
CH(CH
3
)CH
2
CH
2 -, -CH(CH 2
CH
3 )-,
-CH(CH
2
CH
3
)CH
2 -, and -CH 2
CH(CH
2
CH
3
)CH
2 -. 25 Examples of linear partially unsaturated C 3
-
1 2 alkylene groups (C 3 _ 12 alkenylene, and alkynylene groups) include, but are not limited to, -CH=CH-CH 2 -, -CH 2
-CH=CH
2 -, -CH=CH-CH 2
-CH
2 -, -CH=CH-CH 2
-CH
2
-CH
2 -, -CH=CH-CH=CH-, -CH=CH-CH=CH-CH 2 -, -CH=CH-CH=CH-CH 2
-CH
2 -, -CH=CH
CH
2 -CH=CH-, -CH=CH-CH 2
-CH
2 -CH=CH-, and -CH 2
-C=C-CH
2
-
30 Examples of branched partially unsaturated C3 12 alkylene groups
(C
3 1 2 alkenylene and alkynylene groups) include, but are not limited to, -C(CH 3 )=CH-, -C(CH 3
)=CH-CH
2 -, -CH=CH-CH(CH 3 )- and -CCC
CH(CH
3
)-
35 Examples of alicyclic saturated C3 12 alkylene groups (C3- 1 2 cycloalkylenes) include, but are not limited to, cyclopentylene WO 2004/043963 PCT/GB2003/004963 21 (e.g. cyclopent-1,3-ylene), and cyclohexylene (e.g. cyclohex-1,4-ylene). Examples of alicyclic partially unsaturated C 3 1 2 alkylene groups 5 (C 3 12 cycloalkylenes) include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1,3-ylene), cyclohexenylene (e.g. 2-cyclohexen-1,4-ylene; 3-cyclohexen-1,2-ylene; 2,5-cyclohexadien-1,4-ylene). 10 Includes Other Forms Unless otherwise specified, included in the above are the well known ionic, salt, solvate, and protected forms of these substituents. For example, a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO~), a 15 salt or solvate thereof, as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-N HRR 2), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a reference to a hydroxyl 20 group also includes the anionic form (-0), a salt or solvate thereof, as well as conventional protected forms. Isomers, Salts, Solvates, Protected Forms, and Prodrugs Certain compounds may exist in one or more particular geometric, 25 optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and 1-forms; (+) and (-) forms; 30 keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal and anticlinal-forms; a- and p-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms"). 35 Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers", as used herein, WO 2004/043963 PCT/GB2003/004963 22 are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH 3 , is not to be construed as a reference to its 5 structural isomer, a hydroxymethyl group, -CH 2 0H. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g. Cia 10 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl). The above exclusion does not pertain to tautomeric forms, for 15 example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro. HH H -C- C=C C=C' H/ 20 keto enol enolate Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H, 2H (D), and 3H (T); C 25 may be in any isotopic form, including 12C, "C, and 14C; 0 may be in any isotopic form, including 160 and 180; and the like. Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) 30 racemic and other mixtures thereof. Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner. 35 WO 2004/043963 PCT/GB2003/004963 23 Unless otherwise specified, a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below. 5 It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge, et al., J. Pharm. Sci., 66, 1-19 (1977) 10 For example, if the compound is anionic, or has a functional group which may be anionic (e.g. -COOH may be -C00-), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal 15 ions such as Na' and K+, alkaline earth cations such as Ca2 and Mg2+, and other cations such as Al+ 3 . Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e. NH,+) and substituted ammonium ions (e.g. NH 3 R+, NH 2
R
2 +, NHR 3 *, NR 4 *) . Examples of some suitable substituted ammonium ions are those 20 derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary 25 ammonium ion is N(CH 3
)
4 +. If the compound is cationic, or has a functional group which may be cationic (e.g. -NH 2 may be -NH 3 *), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions 30 include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous. Examples of suitable organic anions include, but are not limited 35 to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, WO 2004/043963 PCT/GB2003/004963 24 ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, 5 pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl 10 cellulose. It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate of the active compound. The term "solvate" is used herein in the conventional sense to refer to a 15 complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono hydrate, a di-hydrate, a tri-hydrate, etc. 20 Solvates of particular relevance to the present invention are those where the solvent adds across the imine bond of the PBD moiety, which is illustrated below where the solvent is water or an alcohol (RAOH, where RA is an ether substituent as described above): H H ORA OH OR N H H 2 0 N_ H RAOH N N H R .- R .- R N N N 25 O R O R O R These forms can be called the carbinolamine and carbinolamine ether forms of the PBD. The balance of these equilibria depend on the conditions in which the compounds are found, as well as the nature of the moiety itself. 30 In general any nuceleophilic solvent is capable of forming such solvates as illustrated above for hydoxylic solvents. Other nuceleophilic solvents include thiols and amines.
WO 2004/043963 PCT/GB2003/004963 25 It may be convenient or desirable to prepare, purify, and/or handle the active compound in a chemically protected form. The term "chemically protected form" is used herein in the 5 conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g. pH, temperature, radiation, solvent, and the like). In practice, well known chemical methods are employed to reversibly render 10 unreactive a functional group, which otherwise would be reactive, under specified conditions. In a chemically protected form, one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group). By protecting a reactive functional 15 group, reactions involving other unprotected reactive functional groups can be performed, without affecting the protected group; the protecting group may be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. See, for example, "Protective Groups in Organic 20 Synthesis" (Green, T. and Wuts, P.; 3rd Edition; John Wiley and Sons, 1999). A wide variety of such "protecting", "blocking", or "masking" methods are widely used and well known in organic synthesis. For 25 example, a compound which has two nonequivalent reactive functional groups, both of which would be reactive under specified conditions, may be derivatized to render one of the functional groups "protected", and therefore unreactive, under the specified conditions; so protected, the compound may be used 30 as a reactant which has effectively only one reactive functional group. After the desired reaction (involving the other functional group) is complete, the protected group may be "deprotected" to return it to its original functionality. 35 For example, a hydroxy group may be protected as an ether (-OR) or an ester (-OC(=O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) WO 2004/043963 PCT/GB2003/004963 26 ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (-OC(=O)CH 3 , -OAc). For example, an aldehyde or ketone group may be protected as an 5 acetal (R-CH(OR) 2 ) or ketal (R 2
C(OR)
2 ), respectively, in which the carbonyl group (>C=O) is converted to a diether (>C(OR) 2 ), by reaction with, for example, a primary alcohol. The aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid. 10 For example, an amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH 3 ); a benzyloxy amide (-NHCO-OCH 2
C
6
H
5 , -NH Cbz); as a t-butoxy amide (-NHCO-OC(CH 3
)
3 , -NH-Boc); a 2-biphenyl 15 2-propoxy amide (-NHCO-OC(CH 3
)
2
C
6
H
4
CEH
5 , -NH-Bpoc), as a 9 fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-Alloc), as a 2(-phenylsulphonyl)ethyloxy amide (-NH-Psec); 20 or, in suitable cases (e.g., cyclic amines), as a nitroxide radical (>N-O'). For example, a carboxylic acid group may be protected as an ester for example, as: an CN7 alkyl ester (e.g. a methyl ester; a t 25 butyl ester); a C 1 -7 haloalkyl ester (e.g. a C 1 7 trihaloalkyl ester); a triC 1 7 alkylsilyl-C 1 7 alkyl ester; or a C5-20 aryl-C, 7 alkyl ester (e.g. a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide. 30 For example, a thiol group may be protected as a thioether (-SR), for example, as: a benzyl thioether; an acetamidomethyl ether (
S-CH
2 NHC (=O) CH 3 ) . It may be convenient or desirable to prepare, purify, and/or 35 handle the active compound in the form of a prodrug. The term "prodrug", as used herein, pertains to a compound which, when metabolised (e.g. in vivo), yields the desired active compound.
WO 2004/043963 PCT/GB2003/004963 27 Typically, the prodrug is inactive, or less active than the active compound, but may provide advantageous handling, administration, or metabolic properties. 5 For example, some prodrugs are esters of the active compound (e.g. a physiologically acceptable metabolically labile ester). During metabolism, the ester group (-C(=O)OR) is cleaved to yield the active drug. Such esters may be formed by esterification, for example, of any of the carboxylic acid groups (-C(=O)OH) in 10 the parent compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required. Also, some prodrugs are activated enzymatically to yield the 15 active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative. 20 In particular, prodrugs of pyrrolobenzodiazepines are described in WO 00/12507, which is incorporated herein by reference. In these prodrugs a nitrogen protecting group which can be removed in vivo (e.g. enzymatically, using light) is bound to the 25 nitrogen of the imine group, with the carbon of the imine group bearing a hydroxy, ester or thioester group. Examples of this form of protection include: 2 N OOH Y >OH N which is nitroreductase labile (e.g. using 30 ADEPT/GDEPT); WO 2004/043963 PCT/GB2003/004963 28 MeO MeO 0 r00H 0 Y0 O MeYO OH O OH
NO
2 N N and , which are photolabile; and Me /O 'S O OH N which is glutathione labile (e.g. using NPEPT). 5 General synthetic routes A key intermediate in the synthesis of the compounds of the present invention is the following compound, an enol triflate, of formula (A):
R
9 SEM 1 0 8 R) N H R N 6 OTf 10 R O wherein the groups R 6 to R9 are as for the final product, SEM represents a trimethyl silyl ethoxy methyl group, and OTf represents the group OSO 2
CF
3 . The synthesis of this compound is described in detail in WO 00/12508, which is incorporated herein 15 by reference. In particular, reference is made to scheme 7 on page 24, where the above compound is designated as intermediate P. The SEM protecting group can be replaced by other suitable nitrogen protecting groups. 20 The route from this compound to the desired final product is illustrated in scheme 1.
WO 2004/043963 PCT/GB2003/004963 29
R
9 SEM R 9 SEM I 0 I 0 8) NN8 R H R N H R_ N OTf R 6 N 2 R 6 R O (A) (B) R R N_ H (I) R N/ 2 R O Scheme 1 The key enol triflate intermediate (A) can be converted to the 5 appropriate SEM protected dilactam (B) by use of a Suzuki coupling reaction, i.e. palladium catalysed cross coupling of the enol triflate (A) with the appropriate arylboron derivative. The SEM protected dilactam (B) can then by converted to the 10 desired final compound of formula (I) by reduction, which leads to a protected carbinolamine intermediate, which can then be treated to remove the SEM protecting group. The reduction of the dilactam (B) can be accomplished by, for example, sodium tetraborohydride, whilst a suitable means for removing the SEM 15 protecting group is treatment with silica gel. This synthesis route is equally applicable to the synthesis of dimers. 20 Further Uses The present invention also provides compounds as described in the first aspect of the invention which regulate (e.g. inhibit) cell proliferation. Thus, the present invention also provides methods of regulating (e.g. inhibiting) cell proliferation, in vitro or 25 in vivo, comprising contacting a cell with an effective amount of a compound of the first aspect of the invention.
WO 2004/043963 PCT/GB2003/004963 30 In particular, this inhibition may be of certain cell lines as disclosed in the examples. One of ordinary skill in the art is readily able to determine 5 whether or not a candidate compound regulate (e.g. inhibit) cell proliferation. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below. 10 For example, a sample of cells (e.g. from a tumour) may be grown in vitro and a test compound brought into contact with said cells, and the effect of the compound on those cells observed. As an example of "effect" the morphological status of the cells (e.g. alive or dead, etc.) may be determined. Where the test 15 compound is found to exert an influence on the cells, this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type. 20 Methods of Treatment As described above, the second aspect of the invention provide the use of a compound of the first aspect of the invention in a method of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a 25 therapeutically-effective amount of a compound of the first aspect of the invention, preferably in the form of a pharmaceutical composition, which is the third aspect of the present invention. The term "therapeutically effective amount" is an amount sufficient to show benefit to a patient. Such 30 benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and 35 other medical doctors.
WO 2004/043963 PCT/GB2003/004963 31 A compound may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Examples of treatments and therapies include, but are not limited to, chemotherapy (the 5 administration of active agents, including, e.g. drugs; surgery; and radiation therapy. Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may 10 comprise, in addition to the active ingredient, i.e. a compound of formula I, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The 15 precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous. Pharmaceutical compositions for oral administration may be in 20 tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide 25 solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such a gelatin. For intravenous, cutaneous or subcutaneous injection, or 30 injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles 35 such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, WO 2004/043963 PCT/GB2003/004963 32 antioxidants and/or other additives may be included, as required. Preferences The following preferences may apply to all aspects of the 5 invention as described above, or may relate to a single aspect. The preferences may be combined together in any combination. R' to R' If the compound is a dimer, it is preferred that the dimer bridge 10 is of formula -O-(CH 2 )n-O-, where n is from 3 to 12, and more preferably 3 to 7.
R
9 is preferably H. 15 R 6 is preferably selected from H, OH, OR, SH, NH 2 , nitro and halo, and is more preferably H or halo, and most preferably is H. R7 and R 8 (when the compound is not a dimer) are preferably independently selected from H, OH, OR, SH, SR, NH 2 , NHR, NHRR', 20 and halo, and more preferably independently selected from H, OH and OR, where R is preferably selected from optionally substituted C 1 alkyl, C 3 _10 heterocyclyl and C 5
-
10 aryl groups. Particularly preferred substituents at the 7- and 8- positions are OMe and OCH 2 Ph. 25 R 2 In one set of embodiments R 2 is an optionally substituted napthyl group. Preferred substituents include: halo, more particularly chloro and fluoro; C1-7 alkyl groups, more particularly C 1 4 alkyl 30 groups, e.g. methyl and t-butyl; ether groups, more particularly Ci- alkoxy groups, e.g. methoxy and benzyloxy; C5- 2 0 aryl groups, particularly phenyl. The napthyl group may be linked to the main PBD moiety at any 35 position on its ring system. For example, if the napthyl is unsubstituted, then the group may either be napth-1-yl or napth- WO 2004/043963 PCT/GB2003/004963 33 2-yl, with napth-2-yl being preferred. Especially preferred napthyl groups include: napth-2-yl, 6 methoxy-napth-2-yl, 6-ethoxy-napth-2-yl and fluoro and/or chloro 5 substituted napthyl groups, with single substituted fluoro or chloro napth-2-yls being most preferred. The optional substituents may also be at any ring position. It is preferred that there is not one substituent group either side 10 of the bond to the main PBD moiety. In one set of embodiments R 2 is an optionally substituted thiophenyl group. Preferred substituents include: halo, more particularly chloro and fluoro; C1 7 alkyl groups, more 15 particularly C 1 4 alkyl groups, e.g. methyl and t-butyl; ether groups, more particularly C14 alkoxy groups, e.g. methoxy and benzyloxy; Cs- 2 0 aryl groups, particularly phenyl. The thiophenyl group may be linked to the main PBD moiety at any 20 available position on its ring system. For example, if the thiophenyl is unsubstituted, then the group may either be thiophen-2-yl or thiophen-3-yl, with thiophen-2-yl being preferred. 25 Especially preferred thiophenyl groups include: thiophen-2-yl, 5 chloro-thiophen-2-yl and 5-methyl-thiophen-2-yl. The optional substituents may also be at any ring position. If the thiophenyl group is thiophen-3-yl, then it is preferred that 30 there is not one substituent group either side of the bond to the main PBD moiety. In one set of embodiments R 2 is an optionally substituted furanyl group. Preferred substituents include: halo, more particularly 35 chloro and fluoro; C 1 7 alkyl groups, more particularly C 1 4 alkyl groups, e.g. methyl and t-butyl; ether groups, more particularly WO 2004/043963 PCT/GB2003/004963 34 C1 4 alkoxy groups, e.g. methoxy and benzyloxy; C 5
-
20 aryl groups, particularly phenyl. The furanyl group may be linked to the main PBD moiety at any 5 available position on its ring system. For example, if the furanyl is unsubstituted, then the group may either be furan-2-yl or furan-3-yl, with furan-2-yl being preferred. Especially preferred furanyl groups include: furan-2-yl, 5 10 chloro-furan-2-yl and 5-methyl-furan-2-yl. The optional substituents may also be at any ring position. If the furanyl group is furan-3-yl, then it is preferred that there is not one substituent group either side of the bond to the main 15 PBD moiety. In another set of embodiments R 2 is a phenyl group substituted by an ethyl or propyl group, preferably an ethyl or n-propyl group and more preferably an ethyl group. These groups are preferably 20 in the ortho (2-) or para (4-) positions, with ortho (2-) being more preferred. Thus an especially preferred R 2 group of this type is 4 ethylphenyl. 25 In another set of embodiments R 2 is a phenyl group substituted by one or more chloro or fluoro groups. If there is only one substituent group this is preferably in the ortho (2-) or para (4-) positions, and more preferably in the para (4-) position. 30 If there are two or more substituents, in general the ortho and para positions are the preferred substituent sites. However, it is preferred that there are not two chloro substituents at the 2 and 6- positions. It is also preferred that all the substituents are either fluoro or chloro. 35 Especially preferred R 2 groups of this type are: 4-chlorophenyl; 4-fluorophenyl; 2-chlorophenyl; 2-fluorophenyl; 2,6- WO 2004/043963 PCT/GB2003/004963 35 difluorophenyl; and 3,4-dichlorophenyl. The following compounds are particularly preferred: (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(2-napthyl)-5H-pyrrolo[2,1 5 c][1,4]benzodiazepin-5-one (11); (11aS)-1,lla-dihydro-7,8-dimethoxy-2-(4-tert-butylbenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (13); (ilaS)-1,lla-dihydro-7,8-dimethoxy-2-(4-chlorobenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (15); 10 (1laS)-l,lla-dihydro-7,8-dimethoxy-2-(4-fluorobenzene)-5H pyrrolo(2,1-c][1,4]benzodiazepin-5-one (17); (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(2-methylbenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (19); (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(4-ethylbenzene)-5H 15 pyrrolo[2,1-c][1,4]benzodiazepin-5-one (21); (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(2-thiophenyl)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (23); (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(2-furan)-5H-pyrrolo[2,1 c][1,4]benzodiazepin-5-one (25); and 20 (llaS)-l,lla-dihydro-7,8-dimethoxy-2-(2,6-dimethylbenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (27). The compounds of the first aspect of the invention are preferably used in treating, and in manufacturing medicaments to treat, 25 cancers, and in particular breast, renal and lung cancers and for inhibiting the growth of breast, renal and lung cancer cell lines. In particular, compounds where R 2 is an optionally substitued 30 napthyl or thiophenyl group, are preferably used in treating, and in manufacturing medicaments to treat, lung, breast and renal cancer and melanomas, and more preferably breast cancer. Compounds where R 2 is a phenyl group with an ethyl or propyl 35 substituent are preferably used in treating, and in manufacturing medicaments to treat, lung, breast and renal cancer and WO 2004/043963 PCT/GB2003/004963 36 melanomas. Compounds where R 2 is a phenyl group with one or more fluoro substituents (preferably a 4-fluoro substituent) are preferably 5 used in treating, and in manufacturing medicaments to treat, renal cancer. Compounds where R 2 is a phenyl group with a 4-t-butyl substituent, one or more chloro substituents (preferably a 4-chloro 10 substituent), or a 2-methyl substituent are preferably used in treating, and in manufacturing medicaments to treat, breast cancer. Compounds where R2 is a phenyl group with a 4-t-butyl substituent are also preferably used in treating, and in manufacturing medicaments to treat, melanomas and renal cancer. 15 Compounds where R2 is a phenyl group with a 2-methyl substituent are preferably used in treating, and in manufacturing medicaments to treat, renal cancer. 20 Compounds where R2 is a phenyl group with 2,6-dimethyl substituents are preferably used in treating, and in manufacturing medicaments to treat, renal cancer. 25 Examples General Experimental Methods Melting points (mp) were determined on a Gallenkamp P1384 digital melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded using a Perkin-Elmer 297 spectrophotometer. 30 'H- and 1 3C- NMR spectra were recorded on either a Jeol GSX 270 MHZ FT-NMR spectrometer or a Brucker AMX-250 MHz NMR spectrometer operating at 20 0 C +/-1*C. Chemical shifts are reported in parts per million (5) downfield from tetramethylsilane (TMS). Spin multiplicities are described as: s (singlet), bs (broad singlet), 35 d (doublet), dd (doublet of doublets), t (triplet), q (quartet), p (pentuplet) or m (multiplet). Mass spectra (MS) were recorded using a Jeol JMS-DX 303 GC Mass Spectrometer (EI mode: 70eV, WO 2004/043963 PCT/GB2003/004963 37 source 117-147 0 C). Accurate molecular masses (HRMS) were determined by peak matching using perfluorokerosene (PFK) as an internal mass marker, and FAB mass spectra were obtained from a glycerol/thioglycerol/trifluoroacetic acid (1:1:0.1) matrix with 5 a source temperature of 180'C. Optical rotations at the Na-D line were obtained at ambient temperature using a Perkin-Elmer 141 Polarimeter. Analytical results were generally within +/ 0.2% of the theoretical values. Flash chromatography was performed using Aldrich flash chromatography Silica Gel-60 (E. 10 Merck, 230-400 mesh). Automated flash chromatography was carried out on a Jones Flashmaster II. Thin-layer chromatography (TLC) was performed using GF 254 silica gel (with fluorescent indicator) on glass plates. All solvents and reagents, unless otherwise stated, were supplied by the Aldrich Chemical Company Ltd. and 15 were used as supplied without further purification. Anhydrous solvents were prepared by distillation under a dry nitrogen atmosphere in the presence of an appropriate drying agent, and were stored over 4A molecular sieves or sodium wire. Petroleum ether refers to the fraction boiling at 40-60 0 C. 20 WO 2004/043963 PCT/GB2003/004963 38 Synthesis of key intermediate MeO MeOC M NO CO 2Me MeO OH M2PhSO 2 OH MeO N0 OH 0 0 1 2 3 H H 1 0 1 0 MeO N H MeC N H MeOa N MeOa N OH OTBDMS 0 0 4 5 SEM SEM OeOO 6 7 SEM SEM I 01 0 MeO N HMeO N H MeOa N OTDS MeO) N O O OTf 0 0 6 9 WO 2004/043963 PCT/GB2003/004963 39 N-(4,5-dimethoxy-2-nitrobenzoyl)hydroxyproline methyl ester (3) Oxalyl chloride (15.38 g, 121.11 mmol) was added in one portion to a stirred suspension of 2-nitro-4,5-dimethoxybenzoic acid (1) (25.01 g, 110.10 mmol) in anhydrous DCM (100 mL) at room 5 temperature. A catalytic amount of DMF (2 drops) was added and the reaction mixture was allowed to stir for 16 hours under an inert atmosphere. The acid chloride solution was added dropwise to a vigorously stirred solution of the pyrrolo compound (2) (34.90 g, 110.10 mmol; JOC 5, 13, 3621 (1994)) and TEA (45.95 mL, 10 33.36 g, 330.29 mmol) in anhydrous DCM (100 mL) at -20*C. The reaction mixture was allowed to stir for 16 hours at room temperature. The reaction mixture was washed with saturated NaHCO 3 (2 x 200 mL), saturated NH 4 Cl (2 x 200 mL), water (2 x 200 mL), brine (2 x 200 mL) and dried over anhydrous MgSO 4 . 15 Filtration and evaporation of the solvent in vacuo afforded the crude product (3), which was purified by flash column chromatography using EtOAc as eluent. Pure fractions were combined and evaporation of excess eluent in vacuo afforded the product as a foam (33.26 g, 93.9 mmol, 85%). 1 H NMR (270 MHz, 20 CDCl 3 ) 5 7.69 (s, 1H), 6.87 (s, 1H), 5.31 (s, 2H), 4.97-4.82 (m, 1H), 4.44 (br s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 3.81 (s, 3H), 3.54-3.48 (m, 1H), 3.18 (d, 1H, J = 2.02 Hz), 2.87 (br s, 1H), 2.45-2.16 (m, 2H); "C NMR (67.8 MHz, CDCl 3 ) 5 172.6, 172.5, 167.5, 166.8, 154.4, 154.0, 149.3, 137.5, 137.4, 127.0, 126.2, 25 109.5, 107.2, 107.1, 69.9, 69.1, 59.2, 57.4, 56.9, 56.8, 56.6, 56.4, 54.6, 53.5, 52.5, 52.4, 39.4, 38.0. (1laS)-6,7-dimethoxy-2(R)-hydroxy-2,3,5,10,11,lla-hexahydro-5,11 dioxo-1H-pyrrolo[2,1-c][1,4-jbenzodiazepine (4) 30 10% Pd/C catalyst (3.3 g) was added to a solution of 3 (33.0 g, 93.1 mmol) in absolute EtOH (250 mL). The reaction mixture was hydrogenated under pressure using a Parr hydrogenator at 55 psi H 2 for 18 hours. The reaction mixture was filtered through celite, and the celite washed with hot MeOH, taking care not to allow the 35 filter cake to dry out. Removal of excess solvent afforded the crude product (20.14 g). The crude product was allowed to stir WO 2004/043963 PCT/GB2003/004963 40 in 1 N HC1 (200 mL) and CHCl3 (200 mL) for 30 minutes. The organic layer was washed with 1 N HC1 (100 mL) and the aqueous layers were combined and neutralised with saturated aqueous NaHCO3. On leaving the aqueous extract overnight, a fine white 5 precipitate formed (4) which was collected by filtration and dried (7.81 g, 26.72 mmol, 29 %). 1 H NMR (270 MHz, CDCl) 6 10.06 (s, 1H, NH), 7.61 (s, 1H, ArH), 7.36 (s, 1H, ArH), 4.49-4.41 (m, 1H, 2), 4.22-4.17 (m, 1H, lla), 3.88 (s, 6H), 3.82-3.55 (m, 2H, 3), 3.20 (br s, 1H, OH), 2.87-2.77 (m, 1H, 1), 2.10-2.05 (m, 1H, 10 1); "C NMR (CDCl 3 )5 170.2, 165.9, 152.0, 145.7, 130.7, 118.2, 111.9, 104.2, 68.1, 56.0, 55.6, 54.2, 34.6, 18.8. (IlaS)-6,7-dimethoxy-2(R)-[(tert-butyldimethylsilyl)oxy] 2,3,5,10,11,lla-hexahydro-5,11-dioxo-1H-pyrrolo(2,1-c][1,4 15 ]benzodiazepine (5) Solid TBDMS Chloride (8.22 g, 54.44 mmol) was added in one portion to a solution of 4 (7.23 g, 24.74 mmol) and imidazole (8.42 g, 123.72 mmol) in anhydrous DMF (75 mL) and allowed to stir at room temperature for 16 hours. The reaction mixture was 20 poured into water (500 mL) and filtered to afford the crude product (5), which was purified by recrystallisation from EtOH (800 mL) as fine white needles (6.995 g, 17.21 mmol, 70 %). 1H NMR (270 MHz, CDCl 3 ) 5 10.06 (s, 1H, NH), 7.37 (s, 1H, ArH), 6.68 (s, 1H, ArH), 4.19-4.14 (m, 1H, 2), 4.06-4.01 (m, lH, lla), 3.90 25 (s, 3H, OMe), 3.88 (s, 3H, OMe), 3.69-3.63 (m, 2H, 3), 2.85-2.80 (m, 1H, 1), 2.05-2.01 (m, 1H, 1); 1 3 C NMR (67.8 MHz, CDCl 3 ) 6 170.4, 170.2, 165.9, 152.1, 145.8, 145.6, 131.1, 130.7, 118.1, 111.9, 104.3, 104.1, 69.2, 69.1, 56.0, 55.9, 55.7, 54.3, 54.0, 35.0, 25.8, 25.7, 25.6, 17.9, -3.0, -3.5, -4.9, -5.0. 30 (11aS)-6,7-dimethoxy-2(R)-[(tert-butyldimethylsilyl)oxy] 2,3,5,10,11,1la-hexahydro-10-[2-(trimethylsilyl)ethoxymethyl) 5,11-dioxo-lH-pyrrolo(2,1-c][1,4-]benzodiazepine (6) A solution of 5 (6.50 g, 15.99 mmol) in anhydrous DMF (27.5 mL) 35 was added dropwise to a stirred suspension of NaH (0.422 g, 0.704 WO 2004/043963 PCT/GB2003/004963 41 g of a 60 % dispersion in mineral oil, 18.34 mmol) at 0 0 C and the reaction mixture was allowed to stir for 30 minutes. A solution of SEM chloride (3.11 mL, 2.93 g, 17.59 mmol) in anhydrous DMF (5 mL) was added dropwise to the stirred reaction mixture at 0*C and 5 allowed to stir at room temperature for 16 hours. The reaction mixture was poured into water (200 mL) to afford a white precipitate, which was extracted with diethyl ether (4 x 300 mL). The organic layer was washed with water (2 x 50 mL), brine (2 x 50 mL) and dried over anhydrous MgSO 4 . Filtration and evaporation 10 of the solvent in vacuo afforded the crude product, which was purified by flash column chromatography using an 80:20 mixture of petroleum ether:EtOAc as eluent. Pure fractions were combined and evaporated in vacuo to afford the product (6) as a yellow oil (7.01 g, 13.1 mmol, 82 %). 1 H NMR (270 MHz, CDCl 3 ) 5 7.35 (s, 1H, 15 ArH), 7.24 (s, 1H, ArH), 5.52 (d, 2H, J= 9.89 Hz, SEM amino acetal CH 2 ), 4.65 (d, 2H, J = 9.90 Hz, SEM amino acetal CH 2 ), 4.61-4.56 (m, 1H, 2), 4.23 (dd, 1H, J = 4.40 Hz, 8.24 Hz, lla), 3.94 (s, 3H, OMe), 3.92 (s, 3H, OMe), 3.68 (m, 4H, SEM 1= CH 2 + 3), 2.86 (m, 1H, 1), 2.02 (m, 1H, 1), 0.98 (t, 2H, J = 8.25 Hz, 20 SEM 2= CH 2 ), 0.88 (s, 9H, TBDMS t-Bu CH 3 ), 0.10 (s, 6H, 2 x TBDMS SiCH 3 ), 0.03 (s, 9H, 3 x SEM SiCH 3 ); l3C NMR (67.8 MHz, CDCl 3 ) 5 170.0, 165.6, 151.8, 147.1, 133.9, 121.5, 111.2, 105.5, 78.1, 69.6, 67.0, 56.5, 56.2, 56.1, 53.6, 35.5, 25.7, 18.4, -1.3, -4.8. 25 (1laS)- 6 ,7-dimethoxy-2(R)-hydroxy-2,3,5,10,11,11a-hexahydro-10
[
2 -(trimethylsilyl)ethoxymethyl]-5,11-dioxo-1H-pyrrolo(2,1 c][1,4-Jbenzodiazepine (7) A solution of 1 N TBAF in THF (19.58 mL, 19.58 mmol) was added to a stirred solution of 6 (7.0 g, 13.05 mmol) in THF (50 mL). The 30 reaction mixture was allowed to stir at room temperature for 2 hours and diluted with DCM (200 mL), washed with water (2 x 200 mL), brine (2 x 200 mL) and dried over anhydrous MgSO 4 . Filtration and removal of excess solvent afforded the crude product, which was purified by flash column chromatography using 35 50:50 petroleum ether:EtOAc as eluent. Evaporation in vacuo of the pure fractions afforded the product (7) (5.9 g). 1 H NMR (270 WO 2004/043963 PCT/GB2003/004963 42 MHz, CDC1 3 ) 5 7.30 (s, 1H, ArH), 7.24 (s, 1H, ArH), 5.52 (d, 1H, J = 9.9 Hz, SEM amino acetal CH 2 ), 4.68-4.64 (m, 2H, SEM amino acetal CH 2 + 2), 4.30 (dd, 1H, J = 5.86, 8.24 Hz), 3.91 (s, 3H, OMe), 3.90 (s, 3H, OMe), 3.87-3.51 (m, 4H, SEM 1= CH 2 + 3), 2.95 5 (dt, 1H, J = 5.31, 13.56 Hz, 1), 2.17-2.08 (m, 1H, 1), 1.02-0.93 (m, 2H, SEM 2= CH 2 ), 0.03 (s, 9H, 3 x SiCH 3 ); 13C NMR (67.8 MHz, CDC3l) 5 169.7, 165.9, 151.9, 147.1, 134.0, 121.1, 111.2, 105.5, 78.2, 69.1, 67.1, 56.5, 56.1, 53.9, 34.9, 18.4, -1.3. 10 (1laS)-6,7-dimethoxy-2,3,5,10,11,lla-hexahydro-10-[2 (trimethylsilyl)ethoxymethyl]-2,5,11-trioxo-1H-pyrrolo[2,1 c][1,4-Jbenzodiazepine (8) Anhydrous DMSO (3.28 g, 41.94 mmol) in dry DCM (20 mL) was added dropwise over 5 minutes to a stirred solution of oxalyl chloride 15 (10.48 mL of a 2 N solution in DCM, 20.97 mmol) under a nitrogen atmosphere at -50 0 C. After stirring for 5minutess, a solution 7 (5.90 g, 13.98 mmol), in dry DCM (45 mL) was added dropwise over 45 minutes to the reaction mixture, which was then stirred for a further 45 minutes at -500C. TEA (9.89 g; 97.87 mmol) was added 20 dropwise to the mixture over 15 minutes followed by stirring for a further 15 minutes. The reaction mixture was left to warm to room temperature, diluted with H 2 0 (150 mL) and DCM (100 mL). The organic phase was washed with 1 N HCl (2 x 100 mL), water (2 x 100 mL), brine (2 x 100 mL) and dried over MgSO 4 . Filtration and 25 evaporation afforded the crude product (8), which was purified by flash column chromatography using 50:50 petroleum ether (40 600):EtOAc as eluent. Evaporation of the pure fractions in vacuo afforded the product (4.33 g, 10.3 mmol, 74 %). 'HNMR (270 MHz, CDC13) 6 7.30 (s, 1H, ArH), 7.24 (s, 1H, ArH), 5.60 (d, 1H, J = 30 9.89 Hz, SEM amino acetal CH 2 ), 4.69 (d, 1H, J = 9.89 Hz, SEM amino acetal CH 2 ), 4.62 (dd, 1H, J = 9.89, 3.12 Hz, lla), 4.26 4.19 (m, 1H, 3), 3.95 (s, 3H, OMe), 3.94 (s, 3H, OMe), 3.81-3.49 (m, 4H, SEM 1= CH 2 + 1 + 3), 2.82-2.71 (m, 1H, 1), 0.95 (t, 2H, J = 2.01 Hz, SEM 2= CH 2 ), -0.04 (s, 9H, SEM CH3); "C NMR (67.8 MHz, 35 CDC1 3 ) 5 206.8, 168.8, 165.9, 152.4, 147.5, 134.0, 120.4, 111.1, 105.6, 78.2, 67.2, 56.2, 54.8, 52.3, 37.3, 18.3, -1.3.
WO 2004/043963 PCT/GB2003/004963 43 (1laS)-5,10,11,1la-tetrahydro-7,8-dimethoxy-10-(2 (trimethylsilyl) ethoxymethyl] -2 [((trifluoromethyl)sulphonyl]oxy]-5,11-dioxo-1H-pyrrolo(2,1 5 c][1,4]benzodiazepine (9) Anhydrous pyridine (0.46 mL, 0.452 g, 5.73 mmol) was added in one portion to a vigorously stirred solution of 8 (2.0 g, 4.77 mmol) in anhydrous DCM (100 mL) and the mixture left to stir for 10 minutes at room temperature. Anhydrous triflic anhydride (1.25 10 mL, 1.48 g, 5.25 mmol) was added quickly, in one portion, and the reaction mixture was allowed to stir at room temperature for 4.5 hours. The darkened, homogenous reaction mixture was poured into cold saturated NaHCO 3 (200 mL) and the mixture was extracted with DCM (3 x 50 mL). The organic layers were combined, washed with 15 water (2 x 200 mL), brine (2 x 200 mL) and dried over anhydrous MgSO 4 . Filtration and evaporation afforded the crude product, which was purified by flash column chromatography using 80:20 petroleum ether:EtOAc as eluent. Evaporation of the pure fractions in vacuo afforded the product (9) as a yellow oil (1.79 20 g, 3.25 mmol, 68 %). H NMR (270 MHz, CDCl 3 ) 5 7.29 (s, 1H, ArH), 7.23 (s, 1H, ArH), 7.15 (t, 1H, J = 2.01 Hz, H3), 5.53 (d, 1H, J = 10.07 Hz, SEM amino acetal CH 2 ), 4.68 (d, 1H, J = 9.89 Hz, SEM amino acetal CH 2 ) - WO 2004/043963 PCT/GB2003/004963 44 Example 1: Synthesis of (11aS)-1,lla-dihydro-7,8-dimethoxy-2-(2 napthyl) -5H-pyrrolo [2,1-c] [1, 4]benzodiazepin-5-one (11) SEM SEM 1 0 SEo MeO N H MeO N H MeO N OTf MeO N 0 0'7 910 MeO N_ H I MeO N 0 7 11 (a) 2-(2-napthyl)-7,8-dimethoxy-10-(2-trimethylsilanyl 5 ethoxymethyl)-1,11a-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine 5-one (10) Sodium carbonate (300 mg, 2.83 mmol), 2-napthaleneboronic acid (171 mg, 0.99 mmol) and tetrakis(triphenylphosphine)palladium(0) (30 mg) were added to a 10 solution of 9 (517 mg, 0.93 mmol) in ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 96 hours. The reaction mixture was diluted with ethyl acetate (220 mL) and washed with water (50 mL) and brine (50 mL) and dried over magnesium sulphate. The crude product was purified by flash 15 column chromatography using 70% ethyl acetate in hexane as eluent to give the pure product 10 as a yellow oil. IH (250 MHz, CDCl 3 ) NMR : 5 7.85-7.71 (m, 4H, Ar-H x 4), 7.67 7.54 (m, 2H, H-3, Ar-H x 1), 7,52-7.39 (m, 3H, H-6, Ar-H x 2), 7.33-7.27 (s, 1H, H-9), 5.58 (d, 1H, J = 9.93 Hz, N-CH 2 -OSEM x 1), 20 4.79-4.66 (m, 2H, N-CH 2 -OSEM x 1, H-11a), 4.11 (d, 1H, J = 16.28 Hz, H-1 x 1), 3.97 & 3.95 (2s, 6H, 7- & 8- MeO), 3.90-3.65 (m, 2H, O-CH 2 -SEM), 3.28 (dd, 1H, J = 10.92, 16.23 Hz, H-1 x 1), 1.00 (t; 2H, J = 8.23 Hz, CH2-SEM) , 0.04 (s, 9H, SEM-Si(CH 3 )3) 25 WO 2004/043963 PCT/GB2003/004963 45 (b) (11aS) -1,1la-dihydro-7,8-dimethoxy-2-(2-napthyl) -5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (11) Solid sodium tetraborohydride (654 mg, 17.2 mmol) was added in three portions at two hourly intervals to a stirred solution of 5 10 (971 mg, 1.8 mmol) in a mixture of anhydrous ethanol (19 mL) and anhydrous THF (37 mL) and left to stir at room temperature for 24 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3x 50 mL). The organic layers were evaporated in vacuo. The crude product was treated 10 with ethanol (50 mL), water (30 mL) and silica gel (18.3 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (20 mL) and dried over anhydrous magnesium sulphate. 15 Filtration and evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70 50 % hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 11 as a yellow powder (151 mg, 0.39 mmol, 22 % yield). 20 1H (250 MHZ, CDCL 3 ) NMR: 5 7.9 (d, 1H, J = 4.0 Hz, H11), 7.86 7.40 (m, 8H, H3, H6, 6 x Ar-H), 6.85 (s, lH, H9), 4.48 (dt, 1H, J = 4.9, 11.2 Hz, Hlla), 3.98 & 3.95 (2s, 6H, 7- & 8-MeO), 3.80 3.46 (m, 2H, 2 x Hl).
WO 2004/043963 PCT/GB2003/004963 46 Example 2: Synthesis of (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(4 tert-butylbenzene) -5H-pyrrolo [2,1-c] [1,4]benzodiazepin-5-one (13) SEM SEM 1 0 I o MeO N H MeO N H MeO N OTf MeO N o 0 9 12 MeO N, H MeO N 0 137N (a) 2-(4-tert-butylbenzene)-7,8-dimethoxy-10-(2-trimethylsilanyl 5 ethoxymethyl)-1,lla-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine 5-one (12) Sodium carbonate (302 mg, 2.85 mmol), 4-tert-butylbenzeneboronic acid (177 mg, 0.99 mmol) and tetrakis(triphenylphosphine)palladium(0) (30 mg) were added to a 10 solution of 9 (502 mg, 0.91 mmol) in ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 41 hours. The reaction mixture was diluted with ethyl acetate (220 mL) and washed with water (50 mL) and brine (50 mL) and dried over magnesium sulphate. The crude product was purified by automated 15 flash column chromatography using a 100 - 50 % hexane in ethyl acetate gradient system as eluent to give the pure product 12 (408 mg, 0.76 mmol, 84 % yield) . 1 H (250 MHz, CDCl 3 ) NMR : 5 7.45-7.29 (m, 7H, H-6 & H-3 & H-9 & Ar-H x 4), 5.56 (d, 1H, J = 9.97 Hz, N-CH 2 -OSEM x 1), 4.78-4.55 20 (m, 2H, N-CH 2 -OSEM x 1, H-lla), 4.04-3.60 (m,.9H, 7- & 8- MeO and H-1 x 1 & O-CH 2 -SEM), 3.16 (dd, 1H, J = 10.35, 15.52 Hz, H-1 x 1), 1.38-1.21 (multiple singlets not all Me groups equivalent, 9H, tert-Bu (CH 3
)
3 ), 1.04-0.80 (m, 2H, CH 2 -SEM), 0.09-(-0.04) (multiple singlets not all Me groups equivalent, 9H, SEM-Si(CH 3
)
3 25 WO 2004/043963 PCT/GB2003/004963 47 (b) (11aS) -1,1la-dihydro-7,8-dimethoxy-2-(4-tert-butylbenzene) 5H-pyrrolo(2,1 -c] [1, 41benzodiazepin-5-one (13) Sodium tetraborohydride (531mg, 14.0 mmol) was added in three portions at 0, 5 and 30 hours to a stirred solution of 12 (398 5 mg, 0.74 mmol) in a mixture of anhydrous ethanol (7.5 mL) and anhydrous THF (15 mL). The reaction mixture was allowed to stir at room temperature for 44 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3x 50 mL). The organic layers were evaporated in vacuo. The crude 10 product was treated with ethanol (50 mL), water (25 mL) and silica gel (7.5 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (20 mL) and dried over 15 anhydrous magnesium sulphate. Filtration and evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 13 as yellow glassy solid (193 mg, 0.49 20 mmol, 67 % yield). 'H (250 MHZ, CDCL 3 ) NMR: 8 7.89 (d, 1H, J = 3.94 Hz, H11), 7.58 7.17 (m, 6H, H3,H6, 4 x Ar-H), 6.84 (s, 1H, H9), 4.49-4.35 (m, 1H, Hlla), 4.05- 3.51 (m, 7H, 7- & 8-MeO, Hl), 3.49- 3.33 (m, 1H, Hl), 1.34 (s, 9H, Ar-tBu). 25 WO 2004/043963 PCT/GB2003/004963 48 Example 3: Synthesis of (11aS)-1,1la-dihydro-7,8-dimethoxy-2-(4 chlorobenzene)-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (15) SEM OEM 1 0 SE MeO N H MeO N H MeO N OTf MeO N O 0 94 CI MeO N H MeO N 0 15 C (a) 2-(4-chlorobenzene)-7,8-dimethoxy-10-(2-trimethylsilanyl 5 ethoxymethyl)-1,lla-dihydro-5H-pyrrolo[2,1-cj[1,4]benzodiazepine 5-one (14) Sodium carbonate (300 mg, 2.83 mmol), chlorobenzeneboronic acid (155.28 mg, 1.00 mmol) and tetrakis(triphenylphosphine)palladium(0) (30 mg) were added to a 10 solution of 9 (500 mg, 0.90 mmol) in ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 46 hours at which point additional chlorobenzeneboronic acid (155 mg, 0.99 mmol) and tetrakis(triphenylphosphine)palladium(0) (30 mg) were added. The solution was stirred for a further 44 hours and then 15 diluted with ethyl acetate (220 mL) and washed with water (50 mL) and brine (50 mL). The solution was dried over magnesium sulphate and purified by flash column chromatography using 70% ethyl acetate in hexane as eluent to give the pure product 14 as a brown oil (411 mg, 0.86 mmol, 95 % yield). 20 'H (250 MHz, CDCl3) NMR : 8 7.46-7.22 (m, 7H, H-3 & H-6 & Ar-H x 4 & H-9), 5.55 (d, 1H J = 9.92 Hz, N-CH 2 -OSEM x 1), 4.77-4.61 (m, 2H, N-CH 2 -OSEM x 1 & H-lla), 4.01-3.87 (m, 7H, H-1 x 1 and 7- & 8 MeO), 3.87-3.63 (m, 2H, O-CH2-SEM), 3.13 (ddd, 1H, J = 2.09, 10.56, 16.15 Hz, H-1 x 1), 0.98 (t, 2H, J = 8.20 Hz, CH 2 -SEM), 25 0.03 (s, 9H, SEM-Si(CH3) 3 ) - WO 2004/043963 PCT/GB2003/004963 49 (b) (llaS)-1,lla-dihydro-7,8-dimethoxy-2-(4-chlorobenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (15) Sodium tetraborohydride (531mg, 14 mmol) was added in three 5 portions at 0, 5 and 12 hours to a stirred solution of 14 (386 mg, 0.75 mmol) in a mixture of anhydrous ethanol (7.5 mL) and anhydrous THF (15 mL) and left to stir at room temperature for 24 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3x 50 mL). The organic layers were 10 evaporated in vacuo. The crude product was treated with ethanol (50 mL), water (25 mL) and silica gel (7.5 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (20 mL) and 15 dried over anhydrous magnesium sulphate. Filtration and evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 15 as a yellow 20 solid (97.5 mg, 0.26 mmol, 35 % yield). 1H (250 MHZ, CDCL3) NMR: 8 7.90 (d, 1H, J = 3.9 Hz, H11), 7.53 (s, 1H, H6), 7.50 (broad s, 1H, H3), 7.32 (s, 4H, 4 x Ar-H), 6.84 (s, 1H H9), 4.44 (ddd, 1H, J = 4.1, 5.3, 11.4 Hz, Hlla), 3.97 & 3.95 (2s, 6H, 7- & 8-MeO), 3.58 (ddd, 1H, J = 1.98, 11.6, 16.3 Hz, 25 Hl), 3.4 (ddd, 1H, J = 1.7, 5.4, 16.3 Hz, Hl).
WO 2004/043963 PCT/GB2003/004963 50 Example 4: Synthesis of (11aS)-1,1la-dihydro-7,8-dimethoxy-2-(4 fluorobenzene)-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (17) SEM SEM M 0 H H MeO N H MeO N H MeOa N ' 7 MeO N OTf : 9 16 F MeO N_ H MeO N 0 17 F (a) 2-(4-fluorobenzene)-7,8-dimethoxy-10-(2-trimethylsilanyl 5 ethoxymethyl)-1,lla-dihydro-5H-pyrrolo[2,1-c](1,4]benzodiazepine 5-one (16) Sodium carbonate (308 mg, 2.91 mmol), 4-fluorobenzeneboronic acid (139 mg, 0.99 mmol) and tetrakis(triphenylphosphine) palladium(0) (30 mg) were added to a solution of 9 (500 mg, 0.90 mmol) in 10 ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 93 hours. The reaction mixture was diluted with ethyl acetate (220 mL) and washed with water (50 mL) and brine (50 mL) and dried over magnesium sulphate. The crude product was purified by automated flash column chromatography using a 100 15 50 % hexane in ethyl acetate gradient system as eluent to give the pure product 16 as a yellow oil (441 mg, 0.88 mmol, 99 % yield). IH (250 MHz, CDCl 3 ) NMR : 8 7.45-7.32 (m, 5H, H-6 & H-3 & Ar-H x 2), 7.27 (s, 1H, H-9), 7.04 (t, 2H, Ar-H x 2), 5.56 (d, 1H, J = 20 9.80 Hz, N-CH 2 -OSEM x 1), 4.72 (d, 1H, J = 9.49 Hz, N-CH 2 -OSEM x 1), 4.65 (dd, 1H, J = 3.28, 10.17 Hz, H-11a), 4.04-3.88 (m, 7H, 7- & 8- MeO and H-1 x 1), 3.88- 3.64 (m, 2H, O-CH 2 -SEM), 3.14 (ddd, 1H, J = 2.26, 10.57, 16.25 Hz, H-1 x 1), 0.99 (t, 2H, J = 8.33 Hz, CH 2 -SEM), 0.03 (s, 9H, SEM-Si(CH 3
)
3 ). 25 WO 2004/043963 PCT/GB2003/004963 51 (b) (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(4-fluorobenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (17) Sodium tetraborohydride (201mg, 5.3 mmol) was added in two portions at 0 and 5 hours to a stirred solution of 16 (429 mg, 5 0.861 mmol) in a mixture of anhydrous ethanol (8.6 mL) and anhydrous THF (17.2 mL). The reaction mixture was allowed to stir at room temperature for 24 hours. The reaction mixture was diluted with water (50mL) and extracted with ethyl acetate (3x 50mL). The organic layers were evaporated in vacuo. The crude 10 product was treated with ethanol (50 mL), water (25 mL) and silica gel (8.6 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (20 mL) and dried over 15 anhydrous magnesium sulphate. Filtration and evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 17 as a yellow glassy solid (139 mg, 0.39 20 mmol, 46 % yield). IH (250 MHZ, CDCL 3 ) NMR: 8 7.90 (d, 1H, J = 3.9 Hz, Hll), 7.53 (s, 1H, H6), 7.45 (s, 1H, H3), 7.40-7.20 (m, 1H, 1 x Ar-H), 7.10-6.90 (m, 3H, 3 x Ar-H), 6.84 (s, 1H, H9), 4.43 (ddd, 1H, J = 4.1, 5.4, 11.4 Hz, Hlla), 3.97 & 3.95 (2s, 6H, 7- & 8-MeO), 3.69- 3.50 (m, 25 1H, Hl), 3.39 (ddd, 1H, J = 1.5, 5.3, 16.3 Hz, Hl).
WO 2004/043963 PCT/GB2003/004963 52 Example 5: Synthesis of (1laS)-l,11a-dihydro-7,8-dimethoxy-2-(2 methylbenzene) -5H-pyrrolo [2,1-cl [1,4]benzodiazepin-5-one (19) SEM SEM 1 0 SE MeO N H MeO OH Me MeO N_ OTf MeO N 0 I 9 18 MeO N_ H Me MeO N O 19 (a) 2-(2-methylbenzene)-7,8-dimethoxy-10-(2-trimethylsilanyl 5 ethoxymethyl)-1,lla-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine 5-one (18) Sodium carbonate (300 mg, 2.83 mmol), 2-methylbenzeneboronic acid (135 mg, 0.99 mmol) and tetrakis(triphenylphosphine)palladium(O)(30 mg) were added to a 10 solution of 9 (500 mg, 0.90 mmol) in ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 20 hours. The reaction mixture was diluted with ethyl acetate (200 mL) and washed with water (50 mL) and brine (50 mL) and dried over magnesium sulphate. The crude product was purified by automated 15 flash column chromatography using a 100 - 50 % hexane in ethyl acetate gradient system as eluent to give the pure product 18 as a yellow oil (439 mg, 0.89 mmol, 98 % yield). H (250 MHz, CDCl 3 ) NMR : 6 7.44-7.09 (m, 7H, H-6 & H-3 & H-9 & Ar-H x 4), 5.59 (d, 1H, J = 9.97 Hz, N-CH 2 -OSEM x 1), 4.78-4.50 20 (m, 2H, N-CH 2 -OSEM x 1, H-11a), 4.06-3.60 (m, 9H, 7- & 8- MeO, 0
CH
2 -SEM, H-1 x 1), 3.22 (dd, 1H, J = 10.23, 16.31 Hz, H-1 x 1), 2.48 (Broad s, 3H, Ar-2-Me), 1.06-0.79 (m, 2H, CH 2 -SEM), 0.03 (broad s, 9H, SEM-Si(CH 3
)
3
).
WO 2004/043963 PCT/GB2003/004963 53 (b) (11aS)-1,lla-dihydro-7,8-dimethoxy-2-(2-methylbenzene)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (19) Sodium tetraborohydride (500 mg, 13.2 mmol) was added in three portions at 0, 5 and 12 hours to a stirred solution of 18 (429 5 mg, 0.87 mmol) in a mixture of anhydrous ethanol (8.5 mL) and anhydrous THF (17.5 mL). The reaction mixture was allowed to stir at room temperature for 24 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The organic layers were evaporated in vacuo. The crude 10 product was treated with ethanol (50 mL), ice water (25 mL) and silica gel (8.5 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (20 mL) and dried over 15 anhydrous magnesium sulphate. Filtration and evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 19 as a yellow solid (74 mg, 0.21 mmol, 20 25 % yield). 1H (250 MHZ, CDCL 3 ) NMR: 8 7.92 (d, 1H, J = 3.9 Hz, Hll), 7.55 (s, 1H, H6), 7.34- 7.14 (m, 5H, H3, 4 x Ar-H), 6.85 (s, 1H, H9), 4.39 (dt, 1H, J = 4.7, 11.4 Hz, Hlla), 3.97 & 3.95 (2s, 6H, 7- & 8 MeO), 3.78- 3.59 (m, 1H, HI), 3.47 (dd, 1H, J = 5.2, 16.2 Hz, 25 Hl), 2.49 (s, 3H, Ar-CH 3
).
WO 2004/043963 PCT/GB2003/004963 54 Example 6: Synthesis of (11aS)-1,lla-dihydro-7,8-dimethoxy-2-(2 methylbenzene) -5H-pyrrolo[2,1-c] [1 ,4]benzodiazepin-5-one (21) SEM SEM 1 0 SEo MeO N H MeO N H MeO N _ MeO N O~ 0 Et 9 20 Et MeO N_ H MeO N 21 Et (a) 2-(4-ethylbenzene)-7,8-dimethoxy-10-(2-trimethylsilanyl 5 ethoxymethyl)-1,lla-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine 5-one (20) Sodium carbonate (302 mg, 2.85 mmol), 4-ethylbenzeneboronic acid (149 mg, 0.993 mmol) and tetrakis(triphenylphosphine) palladium(0) (30 mg) were added to a solution of 9 (501 mg, 0.91 10 mmol) in ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 41 hours. The reaction mixture was diluted with ethyl acetate (220 mL) and washed with water (50 mL) and brine (50 mL) and dried over magnesium sulphate. The crude product was purified by automated flash column chromatography using a 100 15 50 % hexane in ethyl acetate gradient system as eluent to give the pure product 20 as a yellow solid (342 mg, 0.67 mmol, 74 % yield). 'H (250 MHz, CDCl 3 ) NMR : 5 7.46-7.15 (m, 7H, H-6 & H-3 & H-9 & Ar-H x 4), 5.57 (d, 1H, J = 9.88 Hz, N-CH 2 -OSEM x 1), 4.72 (d, 1H, 20 J = 9.95 Hz, N-CH 2 -OSEM x 1), 4.65 (dd, 1H, J = 3.52, 10.85 Hz, H lla), 4.03-3.88 (m, 7H, 7- & 8- MeO and H-1 x 1), 3.88- 3.64 (m, 2H, O-CH 2 -SEM), 3.16 (dd, 1H, J = 10.84, 16.51 Hz, H-1 x 1), 2.66 (q, 2H, J= 7.68 Hz, Ar-CH 2 -Me x 2), 1.24 (t, 3H, J = 7.57 Hz, ArCH 2
-CH
3 ), 0.99 (t, 2H, J = 8.29 Hz, CH 2 -SEM), 0.04 (s, 9H, SEM 25 Si (CH 3 ) 3 ) .
WO 2004/043963 PCT/GB2003/004963 55 (b) (11aS)-1,lla-dihydro-7,8-dimethoxy-2-(2-methylbenzene)-5H pyrrolo(2,1-cl[1,4]benzodiazepin-5-one (21) Sodium tetraborohydride (500 mg, 13.2 mmol) was added in three 5 portions at 0, 5 and 12 hours to a stirred solution of 20 (429 mg, 0.87 mmol) in a mixture of anhydrous ethanol (8.5 mL) and anhydrous THF (17.5 mL). The reaction mixture was allowed to stir at room temperature for 24 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 10 50 mL). The organic layers were evaporated in vacuo. The crude product was treated with ethanol (50 mL), ice water (25 mL) and silica gel (8.5 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers 15 were combined and washed with brine (20 mL) and dried over anhydrous magnesium sulphate. Filtration and evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to 20 afford the pure product 21 as a yellow solid (74 mg, 0.21 mmol, 25 % yield). IH (250 MHZ, CDCL 3 ) NMR: 5 7.92 (d, 1H, J = 3.9 Hz, Hll), 7.55 (s, 1H, H6), 7.34-7.14 (m, 5H, H3, 4 x Ar-H), 6.85 (s, 1H, H9), 4.39 (dt, 1H, J = 4.7, 11.4 Hz, H1la), 3.97 & 3.95 (2s, 6H, 7- & 8 25 MeO), 3.78-3.59 (m, 1H, Hl), 3.47 (dd, lH, J = 5.2, 16.2 Hz, Hl), 2.49 (s, 3H, Ar-CH 3
).
WO 2004/043963 PCT/GB2003/004963 56 Example 7: Synthesis of (laS)-1,lla-dihydro-7,8-dimethoxy-2-(2 thiophene) -5H-pyrrolo [2,1-c] [1 ,4]benzodiazepin-5-one (23) SEM SEM 1 0 I a MeO N H MeO N H I~ W KI MeO N OTf Meo N s 00 9 22 MeO N_ H MeO N s 0 23 (a) 2- (2-thiophene) -7,8-dimethoxy-10- (2-trimethylsilanyl 5 ethoxymethyl)-1,lla-dihydro-5H-pyrrolo(2,1-c][1,4]benzodiazepine 5-one (22) Sodium carbonate (305 mg, 2.88 mmol), 2-thiopheneboronic acid (127 mg, 0.99 mmol) and tetrakis(triphenylphosphine) palladium(0) (30 mg) were added to a solution of 9 (500 mg, 0.90 mmol) in 10 ethanol/water/benzene (20/20/20 mL) and stirred at room temperature for 164.5 hours and refluxed at 804C for a further 4 hours. The reaction mixture was diluted with ethyl acetate (200 mL) and washed with water (50 mL) and brine (50 mL) and dried over magnesium sulphate. The crude product was purified by 15 automated flash column chromatography using a 100 - 50 % hexane in ethyl acetate gradient system as eluent to give the pure product 22 as a yellow oil (353 mg, 0.73 mmol, 80 % yield). 'H (250 MHz, CDCl 3 ) NMR : 5 7.39 (s, 1H, H-6), 7.32-7.17 (m, 3H, H-3, H-9, Ar-H x 1), 7.06-6.94 (m, 2H, Ar-H x 2), 5.56 (d, 1H, J 20 = 9.97 Hz, N-CH 2 -OSEM x 1), 4.71 (d, 1H, J = 9.91 Hz, N-CH 2 -OSEM x 1), 4.64 (dd, 1H, J = 3.51, 10.56 Hz, H-lla), 4.02-3.88 (m, 7H, 7- & 8- MeO, H-1 x 1), 3.88-3.63 (m, 2H, O-CH 2 -SEM), 3.18 (ddd, 1H, J = 2.38, 10.76, 16.11 Hz, H-1 x 1), 0.99 (t, 2H, J = 8.24 Hz, CH 2 -SEM) , 0 .04 (s, 9H, SEM-Si (CH 3 ) 3 ) 25 WO 2004/043963 PCT/GB2003/004963 57 (b) (1laS)-1,lla-dihydro-7,8-dimethoxy-2-(2-thiophene)-5H pyrrolo[2,1-c] [1, 4jbenzodiazepin-5-one (23) Sodium tetraborohydride (520mg, 13.7 mmol) was added in three portions at 0, 7 and 14 hours to a stirred solution of 22 (333 5 mg, 0.69 mmol) in a mixture of anhydrous ethanol (6.9 mL) and anhydrous THF (13.8 mL) and left to stir at room temperature for 30 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3x 50 mL). The organic layers were evaporated in vacuo and the crude product was treated with 10 ethanol (50 mL), water (25 mL) and silica gel (6.9 g) and left to stir at room temperature for 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL) . The organic layers were combined and washed with brine (20 mL) and dried over anhydrous magnesium sulphate. Filtration and 15 evaporation in vacuo afforded the crude product, which was purified using flash column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 23 as a yellow solid (49.6 mg, 0.15 mmol, 21 % yield). 20 MS (ES) m/z(relative intensity): 389.2 (22), 373.2 (14), 341 (8), 194.3 (100). Example 8: Synthesis of (1laS)-l,lla-dihydro-7,8-dimethoxy-2-(2 furan) -5H-pyrrolo[2,1-c] [1,4]benzodiazepin-5-one (25) SEM SEM I 0 1 0 MeO N H MeO N H MeO N OTf MeO N O 0 0 9 24 MeO N- H MeO N 0 0 25 25 WO 2004/043963 PCT/GB2003/004963 58 (a) 2-(2-furan)-7,8-dimethoxy-10-(2-trimethylsilanyl ethoxynethyl)-1,la-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine 5-one (24) A catalytic amount of tetrakis triphenylphosphine palladium [0] 5 (5 mol%, 73 mg, 0.063 mmol) was added to a stirred mixture of 9(700 mg, 1.27 mmol), LiCl (161 mg, 3.8 mmol), and 2 (tributylstannyl)furan (0.526 mL, 615 mg, 1.65 mmol) in anhydrous THF (20 mL) and heated at reflux for 2 hours. The cooled reaction mixture was diluted with DCM (100 mL) and the mixture 10 washed with 10% aqueous ammonium hydroxide (100 mL). The organic layer was washed with water (100 mL), brine (100 mL), and dried over anhydrous MgSO 4 . Filtration and evaporation of the solvent in vacuo afforded the crude product, which was further purified by flash chromatography using a 75:25 mixture of hexane:EtOAc as 15 eluent. Pure fractions were combined and evaporation of the solvent in vacuo afforded the product 24 (484 mg, 1.03 mmol, 81%). 1 H NMR (CDCl 3 ) 5 7.35 (s, 2H), 7.27 (s, 1H),7.23 (d, Ji=1.5Hz, 1H), 6.37 (dd,Ji=1.7Hz, J 2 =3.2Hz, 1H), 6.26 (d, Ji=3.2Hz), 5.52 20 (d, J=lOHz, 1H, SEM), 4.67 (d, J=lOHz, 1H, SEM), 4.58 (dd, Ji=3.3Hz, J 2 =10.6Hz, 1H, Hlla), 3.91 (s, 3H, OMe), 3.90 (s, 3H, OMe), 3.86-3.74 (m, 2H, 1SEM, l l), 3.69-3.63 (m, 1H, 1SEM), 3.05 (ddd, J 1 =2.0 Hz, J 2 =10.6Hz, J 3 =15.8Hz, lH1), 0.95 (m, 2H, SEM), 0 (s, 9H, SEM). 25 13 C NMR (CDC1 3 )5 169.5, 163, 153.4, 150.6, 148.7, 143.7, 135, 122.6, 122.4, 117.7, 112.7, 108.6, 107.2, 79.7, 68.51, 58.75, 57.5, 31.8, 19.7, 0 IR 2952, 1689, 1640, 1606, 1518, 1453, 1430, 1358, 1276, 1248, 1209, 1102, 1069, 1010, 858, 836, 787, 757. 30 MS ES* 471.2 (M+H, 100%), 353.1 (65%). [a]d=+175*, c=20mg/lOmL, T=18.6 0 C, CHC1 3 . (b) (11aS)-1,11a-dihydro-7,-dimethoxy-2-2furan)-5H pyrrolo[2,1-c][1,4]benzodiazepin-5-one (25) 35 Solid sodium tetraborohydride (NaBH 4 , 95 mg, 2.51mmol) was added in one portion to a rapidly stirred solution of 24 (400mg, 0.85mmol) in a mixture of anhydrous EtOH (3 mL) and anhydrous THF WO 2004/043963 PCT/GB2003/004963 59 (7 mL) at room temperature and allowed to stir for 4 hours. More sodium tetraborohydride (60mg, 1.58 mmol) was added and the mixture left to stir at room temperature overnight. The reaction mixture was diluted with cold water (50 mL) and extracted with 5 EtOAc (2 x 30 mL). The organic layers were washed with brine (30 mL) and dried over anhydrous MgSO 4 . Filtration and evaporation of the solvent in vacuo afforded the crude product which was stirred overnight with silica gel (1 g) in EtOH (10 mL) and water (5 mL). The mixture was then filtered and excess EtOH was removed by 10 rotary evaporation. The remaining mixture was extracted with EtOAc (2 x 20 mL). The organic layers were washed with brine (30 mL) and dried over anhydrous MgSO 4 . Filtration and evaporation of the solvent in vacuo afforded the crude product which was purified by flash column chromatography eluting with a 60:40 15 mixture of hexane:EtOAc. Pure fractions were combined to afford 25 as a yellow solid (80 mg, 0.246 mmol, 29%). IH NMR (CDC1 3 ) 5 7.89 (d, J=4.0 Hz, 1H, H-11), 7.54 (s, 1H),7.42 (d, J=1.4Hz, 1H), 7.38 (s, 1H), 6.84 (s, 1H) 6.44 (dd, Ji=1.7Hz,
J
2 =3.2Hz, 1H), 6.28 (d, J=3.2Hz, 1H), 4.41 (m, 1H, H1la), 3.98 (s, 20 3H, MeO), 3.96 (s, 3H, MeO), 3.50(m, IH1), 3.35 (ddd, Ji=1.6Hz,
J
2 =5.2Hz, J 2 =16.2Hz, 1H, 1Hl). 3 C NMR (CDCl 3 ) 6 163.8, 162.8, 153.4, 150.7, 149.3, 143.9, 141.8, 124.3, 120.5, 115.8, 113.1, 112.9, 111.3, 108.2, 57.7, 57.6, 55.2, 36. 25 IR 3117, 2936, 1626, 1601, 1559, 1508, 1450, 1426, 1377, 1344, 1265, 1215, 1102, 1072, 1039, 1007, 956, 914, 882, 778, 730. MS ES* 325.1 (M+H, 100%). [0]d=+457', c=15mg/lOmL, T=20 0 C. CHCl 3 30 WO 2004/043963 PCT/GB2003/004963 60 Example 9: Synthesis of (11aS)-1,1la-dihydro-7,8-dimethoxy-2 (2,6-dimethylbenzene)-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (27) SEM SEM 1 0 1 0 MeO N H MeO N H Me MeO N OTf MeO N o 0 26 Me MeO N_ H Me MeO N 0 27 Me 5 (a) 2-(2,6-dimethylbenzene)-7,8-dimethoxy-10-(2-triinethylsilanyl ethoxymethyl) -1,1la-dihydro-5H-pyrrolo(2,1-c] [1, 4]benzodiazepine 5-one (26) Sodium carbonate (300 mg, 2.85 mmol), 2,6-dimethylbenzeneboronic acid (149 mg, 0.99 mmol) and 10 tetrakis(triphenylphosphine)palladium(0) (30 mg) were added to a solution of 9 (500 mg, 0.90 mmol) in ethanol/water/benzene (2/2/6 mL) and stirred at room temperature for 306.5 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (20 mL) and brine (20 mL) and dried over 15 magnesium sulphate. The crude product was purified by automated flash column chromatography using a 100 - 50 % hexane in ethyl acetate gradient system as eluent to give the pure product (218 mg, 0.43 mmol, 47 % yield). 20 'H (250 MHz, CDCl 3 ) NMR : 5 7.42 (s, 1H, H-6), 7.28 (s, 1H, H-9), 7.22-7.02 (m, 3H, Ar-H x 3), 6.82 (broad s, 1H, H-3), 5.62 (d, 1H, J = 9.85 Hz, N-CH 2 -OSEM x 1), 4.74 (d, 1H, J = 9.72 Hz, N-CH 2 OSEM x 1), 4.64 (dd, 1H, J = 3.08, 10.51 Hz, H-lla), 3.96 & 3.94 (2s, 6H, 7- & 8- MeO), 3.89-3.64 (m, 3H, O-CH 2 -SEM, H-1 x 1), 3.02 25 (ddd, 1H, J = 2.39, 10.58, 16.89 Hz, H-1 x 1), 2.32 (s, 6H, Ar- WO 2004/043963 PCT/GB2003/004963 61 2,6-diMe x 6), 1.00 (t, 2H, J = 8.27 Hz, CHr-SEM), 0.03 (s, 9H, SEM-Si(CH3),) (b) (1aS) -1,1la-dihydro-7,8-dimethoxy-2- (2,4-dimethyl-benzene) 5 5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (27) Solid sodium tetraborohydride (276 mg, 7.3 mmol) was added in two portions at 0 and 24 hours to a stirred solution of 26 (208 mg, 0.41 mmol) in a mixture of anhydrous ethanol (4.1 mL) and anhydrous THF (8.2 mL). The reaction mixture was allowed to stir 10 at room temperature for 47 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The organic layers were evaporated in vacuo and the crude product was treated with ethanol (50 mL), ice water (25 mL) and silica gel (8.2 g) and left to stir at room temperature for 15 24 hours. The reaction mixture was filtered and the product extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (20 mL) and dried over anhydrous magnesium sulphate. Filtration and evaporation in vacuo afforded the crude product, which was purified using flash 20 column chromatography with a 70%-50% hexane in ethyl acetate as eluent. Pure fractions were combined and evaporated in vacuo to afford the pure product 27 as a yellow solid (43.3 mg, 0.12 mmol, 29 % yield). 1H (250 MHZ, CDCL3) NMR: 8 7.92 (d, 1H, J = 3.9 Hz, Hll), 7.55 (s, 25 1H, H6), 7.34- 7.14 (m, 5H, H3, 4 x Ar-H), 6.85 (s, 1H, H9), 4.39 (dt, 1H, J = 4.7, 11.4 Hz, Hlla), 3.97 & 3.95 (2s, 6H, 7- & 8 MeO), 3.78- 3.59 (m, 1H, Hl), 3.47 (dd, 1H, J = 5.2, 16.2 Hz, H1), 2.49 (s, 6H, Ar-CH3). 30 Biological assays In vitro - clonogenic cell lines In order to determine the activity of the compounds synthesised, solid human tumour xenografts growing subcutaneously in serial passages in thymus aplastic nude mice (Naval Medical Research 35 Institute, USA nu/nu strain) were removed under sterile condition, mechanically disaggregated and subsequently incubated WO 2004/043963 PCT/GB2003/004963 62 with an enzyme cocktail consisting of collagenase (41U/ml, Sigma), DNAse I (125 U/ml, Roche), hyaluronidase (1000 U/ml, Sigma) and dispase II(1.0 U/ml) in RPMI 1640-Medium (Life Technologies) at 37'C for 30 minutes. Cells were passed through 5 sieves of 200 pm and 50 pm mesh size and washed twice with sterile PBS-buffer. The percentage of viable cells was determined in a Neubauer-hemocytometer using trypan blue exclusion. The cells generated were as follows: Breast MACL MCF7 10 Renal 9442 Lung 629L Melanoma MEXF 462NL The clonogenic assay was performed in a 24-well format according 15 to a modified two-layer agar assay introduced by Hamburger, A.W. and Salmon, S.E., Science, 197, 461-643 (1972). The bottom layer consisted of 0.2 ml/well of Iscove's Modified Dulbecco's Medium (supplemented with 20% fetal calf serum and 1% gentamicin) and 0.75% agar. 4 X 10' to 8 x 104 cells were added to 0.2 ml of the 20 same culture medium supplemented with 0.4 % agar and plated in 24-multiwell dishes onto the bottom layer. The test compounds were applied by continuous exposure (drug overlay) in 0.2 ml culture medium. Each dish included six control wells containing the vehicle and drug treated groups in triplicate at 6 25 concentrations. Cultures were incubated at 37*C and 7.5% C02 in a humidified atmosphere for 8-20 days and monitored closely for colony growth using an inverted microscope. Within this period, in vitro tumour growth led to the formation of colonies with a diameter of >50 pm. At the time of maximum colony formation, 30 counts were performed with an automatic image analysis system (OMNICOM FAS IV, Biosys GmbH). 24 hours prior to evaluation, vital colnies were stained with a sterile aqueous solution of 2 (4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (1 mg/ml, 100 pl/well). 35 The IC 50 values of the test compounds were determined by plotting compound concentration versus cell viability.
WO 2004/043963 PCT/GB2003/004963 63 The following compounds (Cooper. N., et al., Chem. Commun., 16, 1764-1765 (2002) and WO 00/12508) were tested as comparisons: MeO N H MeO N- H MeO N MeO N 0 0 C1 C2 OMe MeO N_ H MeO N 0 C3 Me 5 The results are as shown in the following tables. Table 1 - Breast MACL MCF7 Compound IC 50 (nM) C1 19.33 C2 1.96 C3 1.59 11 0.22 13 0.26 15 0.15 19 0.35 21 <0.1 23 0.35 10 Table 2 - Renal RXF 944L Compound IC 50 (nM) Cl 20.50 C2 1.50 C3 0.89 17 0.17 21 <0.1 WO 2004/043963 PCT/GB2003/004963 64 Table 3 - Lung 629L Compound IC 50 (nM) C1 44.50 C2 5.00 C3 8.00 19 1.00 21 0.36 Table 4 - Melanoma MEXF 462NL Compound IC50 (nM) Cl 40.00 C2 2.85 C3 2.00 21 <0.1 5 NCI In Vitro Cytotoxicity Studies The National Cancer Institute (NCI), Bethesda, Maryland, USA has available an in vitro cytotoxicity screen which consists of approximately 60 human tumour cell lines against which compounds are tested at a minimum of five concentrations each differing 10 10 fold. A 48 hour continuous exposure protocol is used, where cell viability or growth is estimated with an SRB protein assay. Method The test compounds were evaluated against approximately 60 human 15 tumour cell lines. The NCI screening procedures were described in detail by Monks and co-workers (Monks, A et al., Journal of the National Cancer Institute, 1991, 83, 757). Briefly, cell suspensions were diluted according to the particular cell type and the expected target cell density (5000-40,000 cells per well 20 based on cell growth characteristics), and added by pipette (100 pL) into 96-well microtitre plates. The cells were allowed a preincubation period of 24 hours at 370C for stabilisation. Dilutions at 'twice the intended test concentration were added at time zero in 100 pL aliquots to the wells. The test compounds 25 were evaluated at five 10-fold dilutions (10-4, 10-5, 10-6, l0o WO 2004/043963 PCT/GB2003/004963 65 and 10-8 pM). The test compounds were incubated for 48 hours in 5% CO 2 atmosphere and 100% humidity. The cells were then assayed using the sulphorhodamine B assay. A plate reader was used to read the optical densities and a microcomputer processed the 5 readings into GI 50 values (in Moles), which is the dosage required to limit cell growth to 50%. The results of these studies can be summarized by averaging log GI50 across all the cell lines tested to derive a MG MID value, 10 which shows that compound 25 (MGMID = -7.18) is more effective than compound 23 (MGMID = -6.34). NCI Hollow Fibre Assay for Preliminary In Vivo Testing The Biological testing Branch of the Developmental Therapeutics 15 Program of the NCI has adopted a preliminary in vivo screening tool for assessing the potential anticancer activity of compounds identified by the large scale in vitro cell screen. For these assays, human tumour cells are cultivated in polyvinylidene (PVDF) hollow fibres, and a sample of each cell line is implanted 20 into each of two physiologic compartments (intraperitoneal and subcutaneaous) in mice. Each test mouse received a total of 6 fibres (3 intraperitoneally and 3 subcutaneously) representing 3 distinct cancer cell lines. These mice are treated with potential antitumour compounds at each of 2 test doses by the 25 intraperitoneal route using a QD x 4 treatment schedule. Vehicle controls consist of 6 mice receiving the compound diluent only. The fibre cultures are collected on the day following the last day of treatment. To assess anticancer effects, the viable cell mass is determined for each of the cell lines using a formazyn 30 dye (MTT) conversion assay. From this, the %T/C can be calculated using the average optical density of compound treated samples divided by the average optical; density of the vehicle controls. In addition, the net increase in cell mass can be determined for each sample, as a sample of fibre cultures are 35 assessed for viable cell mass on the day of implantation into mice. Thus, the cytostatic and cytocidal capacities of the test WO 2004/043963 PCT/GB2003/004963 66 compound can be assessed. Generally, each compound is tested against a minimum of 12 human cancer cell lines. This represents a total of 4 experiments 5 since each experiment contains 3 cell lines. The data are reported as %T/C for each of the 2 compound doses against each of the cell lines with separate values calculated for the intraperitoneal and subcutaneous samples. 10 Compounds are selected for further in vivo testing in standard subcutaneous xenograft models on the basis of several hollow fibre assay criteria. These include: (1) a %T/C of 50 or less in 10 of the 48 possible test combinations (12 cell lines X 2 sites X 2 compound doses); (2) activity at a distance (intraperitoneal 15 drug/subcutaneous culture) in a minimum of 4 of the 24 possible combinations; and/or (3) a net cell kill of 1 or more of the cell lines in either implant site. To simplify evaluation, a points system has been adopted which allows rapid evaluation of the activity of a given compound. For this, a value of 2 is assigned 20 for each compound dose which results in a 50% or greater reduction in viable cell mass. The intraperitoneal and subcutaneous samples are scored separately so that criteria (1) and (2) can be evaluated. Compounds with a combined IP + SC score of 20, a SC score of 8 or a net cell kill of one or more 25 cell lines are referred for xenograft testing. This comparison indicated that there was a very low probability of missing an active compound if the hollow fibre assay was used as the initial in vivo screening tool. In addition to these criteria, other factors (e.g. unique structure, mechanism of action) may result 30 in referral of a compound for xenograft testing without the compound meeting these criteria. Certain compounds of the invention were tested in variations of these assays, to assess their activity against renal and melanoma 35 cell lines. In the melanoma assay, only 6 cell lines are used, and therefore compounds with a combined IP + SC score of 10 or a SC score of 4 are referred for xenograft testing. In the renal WO 2004/043963 PCT/GB2003/004963 67 assay, only three cell lines are used and therefore compounds with a combined IP + SC score of 5 or a SC score of 2 are referred for xenograft testing. 5 The results of this assay are presented below in tables 5 and 6, including results for some of the compounds disclosed in Cooper. N., et al., Chem. Commun., 16, 1764-1765 (2002) and WO 00/12508: Compound IP SC IP + SC Cl 0 0 0 C3 2 0 2 13 4 2 6 27 4 4 8 Table 5 - Renal 10 Compound IP SC IP + SC C1 4 0 4 C3 0 2 2 13 2 4 6 19 4 4 8 21 10 0 10 Table 6 - Melanoma On the basis of these results, compounds 13 and 27 have been 15 selected to be tested in the next stage of the NCI program (xenografts) on renal cancers, whilst compounds 12 and 21 have been selected to be tested on melanomas.

权利要求:
Claims (10)
[1] 1. A compound of formula (I): R 9 R 8 N- H 7 N1. (1) R 6rN - R2 R O 5 and salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R , R 7 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR', nitro, Me 3 Sn and halo; where R and R' are independently selected from optionally 10 substituted Ci-1 alkyl, C3-20 heterocyclyl and C 5 20 aryl groups; R 8 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR', nitro, Me 3 Sn and halo, or the compound is a dimer with each monomer being of formula (I), where the Re groups of each monomers form together a dimer bridge having the formula -X--R"-X- linking the monomers, 15 where R" is a C 3 -1 2 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. 0, S, NH, and/or aromatic rings, e.g. benzene or pyridine, and each X is independently selected from 0, S, or NH; or any pair of adjacent groups from R 6 to R 9 together form a group 20 -O-(CH 2 )p-O-, where p is 1 or 2; and R 2 is selected from: (i) an optionally substituted napthyl group; (ii) an optionally substituted thiophenyl or furanyl group; and (iii) a phenyl group substituted by: 25 (a) one or more chloro or fluoro groups; (b) an ethyl or propyl group; (c) a 4-t-butyl group; (d) a 2-methyl group; or (e) two methyl groups in the 2- and 6- positions. 30
[2] 2. A compound according to claim 1, wherein R 2 is selected from: (i) an optionally substituted napthyl group; WO 2004/043963 PCT/GB2003/004963 69 (ii) an optionally substituted thiophenyl or furanyl group; and (iii) a phenyl group substituted by: (a) one or more chloro or fluoro groups; (b) an ethyl or propyl group; 5 (c) a 4-t-butyl group; or (d) a 2-methyl group.
[3] 3. A compound according to claim 2, wherein R 2 is selected from: 10 (i) an optionally substituted napthyl group; (ii) an optionally substituted thiophenyl group; and (iii) a phenyl group substituted by: (a) one or more chloro or fluoro groups; (b) an ethyl or propyl group; 15 (c) a 4-t-butyl group; or (d) a 2-methyl group.
[4] 4. A compound according to any one of claims 1 to 3, wherein R' is H. 20
[5] 5. A compound according to any one of claims 1 to 4, wherein R6 is H.
[6] 6. A compound according to any one of claims 1 to 5, wherein 25 R and R8 (when the compound is not a dimer) are selected from OMe and OCH 2 Ph.
[7] 7. A compound of any one of claims 1 to 7 for use in a method of therapy. 30
[8] 8. A pharmaceutical composition containing a compound of any one of claims 1 to 7, and a pharmaceutically acceptable carrier or diluent. 35
[9] 9. The use of a compound of any one of claims 1 to 7 in the manufacture of a medicament for treating a proliferative disease. WO 2004/043963 PCT/GB2003/004963 70
[10] 10. A method of treatment of a proliferative disease, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of any one of claims 1 to 7.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2003282251B2|2010-03-18|Pyrrolobenzodiazepines

---

US9624227B2|2017-04-18|Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases

---

EP1720881B9|2013-04-17|11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins

---

EP1723152B1|2015-02-11|Pyrrolobenzodiazepines

---

EP1879901A1|2008-01-23|Pyrrolobenzodiazepines

---

CA2872205A1|2013-11-07|Pyrrolobenzodiazepines

同族专利:

---

公开号 | 公开日

---

DE60336014D1|2011-03-24|

---

JP4750418B2|2011-08-17|

---

ZA200504432B|2006-02-22|

---

US20060128693A1|2006-06-15|

---

WO2004043963A1|2004-05-27|

---

KR101059183B1|2011-08-25|

---

CA2505489C|2011-11-15|

---

CN1735616A|2006-02-15|

---

US7407951B2|2008-08-05|

---

CA2505489A1|2004-05-27|

---

MXPA05005179A|2005-11-17|

---

NZ540050A|2007-02-23|

---

KR20050086643A|2005-08-30|

---

CN100396683C|2008-06-25|

---

AU2003282251B2|2010-03-18|

---

EP1575955B1|2011-02-09|

---

AT497963T|2011-02-15|

---

BR0316241A|2005-10-04|

---

JP2006507313A|2006-03-02|

---

GB0226593D0|2002-12-24|

---

EP1575955A1|2005-09-21|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US3523941A|1967-03-06|1970-08-11|Hoffmann La Roche|Benzodiazepine compounds and process for their preparation|

---

US3524849A|1967-10-27|1970-08-18|Hoffmann La Roche|Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein|

---

DE1965304A1|1968-12-30|1970-07-23|Fujisawa Pharmaceutical Co|Benzdiazepinone compounds and processes for their preparation|

---

IL33558A|1968-12-30|1973-10-25|Fujisawa Pharmaceutical Co|Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production|

---

JPS6053033B2|1976-12-28|1985-11-22|Microbial Chem Res Found||

---

JPS585916B2|1977-12-27|1983-02-02|Green Cross Corp||

---

JPS6237631B2|1979-07-17|1987-08-13|Green Cross Corp||

---

JPH0216315B2|1980-12-31|1990-04-16|Fujisawa Pharmaceutical Co||

---

JPS58180487A|1982-04-16|1983-10-21|Kyowa Hakko Kogyo Co Ltd|Antibiotic dc-81 and its preparation|

---

FR2586683B1|1985-08-29|1988-07-01|Centre Nat Rech Scient|NOVEL NEOTHRAMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS|

---

GB8607679D0|1986-03-27|1986-04-30|Winter G P|Recombinant dna product|

---

MX9203200A|1986-12-19|1992-09-01|Upjohn Co|CC ANALOGS. 1065 NOVELTIES.|

---

GB8705477D0|1987-03-09|1987-04-15|Carlton Med Prod|Drug delivery systems|

---

GB8809616D0|1988-04-22|1988-05-25|Cancer Res Campaign Tech|Further improvements relating to drug delivery systems|

---

US5143854A|1989-06-07|1992-09-01|Affymax Technologies N.V.|Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof|

---

AU648313B2|1990-04-25|1994-04-21|Pharmacia & Upjohn Company|Novel CC-1065 analogs|

---

FR2676230B1|1991-05-07|1993-08-27|Centre Nat Rech Scient|NOVEL PYRROLO [1,4] -BENZODIAZEPINES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM.|

---

US5633158A|1991-10-23|1997-05-27|Cancer Research Campaign Technology Limited|Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form|

---

GB9205051D0|1992-03-09|1992-04-22|Cancer Res Campaign Tech|Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them|

---

US5288514A|1992-09-14|1994-02-22|The Regents Of The University Of California|Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support|

---

US5502068A|1995-01-31|1996-03-26|Synphar Laboratories, Inc.|Cyclopropylpyrroloindole-oligopeptide anticancer agents|

---

CA2225914A1|1995-06-29|1997-01-16|Pharmacopeia, Inc.|Combinatorial 1,4-benzodiazepin-2,5-dione library|

---

GB9516943D0|1995-08-18|1995-10-18|Cancer Soc Auckland Div Nz Inc|Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs|

---

JP4155598B2|1996-09-12|2008-09-24|オークランドユニサーヴィシズリミテッド|Condensed N-acylindoles as anticancer agents|

---

JPH1087666A|1996-09-18|1998-04-07|Kyorin Pharmaceut Co Ltd|Intermediate for producing duocarmycin sa and its derivative and production thereof|

---

IL136489D0|1997-12-08|2001-06-14|Scripps Research Inst|Synthesis of cc-1065/duocarmycin analogs|

---

AU2713799A|1998-03-12|1999-09-27|Novo Nordisk A/S|Modulators of protein tyrosine phosphatases |

---

GB9818732D0|1998-08-27|1998-10-21|Univ Portsmouth|Collection of compounds|

---

GB9818730D0|1998-08-27|1998-10-21|Univ Portsmouth|Collections of compounds|

---

GB9818731D0|1998-08-27|1998-10-21|Univ Portsmouth|Compounds|

---

AT294803T|1998-08-27|2005-05-15|Spirogen Ltd|PYRROLOBENZODIAZEPINE|

---

GB9909612D0|1999-04-26|1999-06-23|Cancer Res Campaign Tech|N-protected amines and their use as prodrugs|

---

US6660856B2|2002-03-08|2003-12-09|Kaohsiung Medical University|Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues|

---

GB0226593D0|2002-11-14|2002-12-24|Consultants Ltd|Compounds|

---

GB0321295D0|2003-09-11|2003-10-15|Spirogen Ltd|Synthesis of protected pyrrolobenzodiazepines|

---

AU2004284075A1|2003-10-22|2005-05-06|Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services|Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto|

---

SI1720881T1|2004-03-01|2013-04-30|Spirogen Sarl|11-hydroxy-5h-pyrrolos2,1-ccs1,4cbenzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins|AT294803T|1998-08-27|2005-05-15|Spirogen Ltd|PYRROLOBENZODIAZEPINE|

---

GB9818730D0|1998-08-27|1998-10-21|Univ Portsmouth|Collections of compounds|

---

GB0226593D0|2002-11-14|2002-12-24|Consultants Ltd|Compounds|

---

GB0321295D0|2003-09-11|2003-10-15|Spirogen Ltd|Synthesis of protected pyrrolobenzodiazepines|

---

GB0404574D0|2004-03-01|2004-04-07|Spirogen Ltd|Amino acids|

---

GB0404577D0|2004-03-01|2004-04-07|Spirogen Ltd|Pyrrolobenzodiazepines|

---

SI1720881T1|2004-03-01|2013-04-30|Spirogen Sarl|11-hydroxy-5h-pyrrolos2,1-ccs1,4cbenzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins|

---

WO2005085260A1|2004-03-09|2005-09-15|Spirogen Limited|Pyrrolobenzodiazepines|

---

GB0410725D0|2004-05-13|2004-06-16|Spirogen Ltd|Pyrrolobenzodiazepine therapeutic agents|

---

ES2338696T3|2005-04-21|2010-05-11|Spirogen Limited|PIRROLOBENZODIAZEPINAS.|

---

AT427949T|2005-10-05|2009-04-15|Spirogen Ltd|4-A4--BUTYRYLAMINOU-1 - PYRROLO-2-CARBON SURREATE CYLENE DERIVATIVES AND RELATED COMPOUND FOR TREATING ONE PROLIFERATIVE DISEASE|

---

GB0813432D0|2008-07-22|2008-08-27|Spirogen Ltd|Pyrrolobenzodiazepines|

---

GB0819097D0|2008-10-17|2008-11-26|Spirogen Ltd|Pyrrolobenzodiazepines|

---

GB0819095D0|2008-10-17|2008-11-26|Spirogen Ltd|Pyrrolobenzodiazepines|

---

GB201006340D0|2010-04-15|2010-06-02|Spirogen Ltd|Synthesis method and intermediates|

---

US20130028917A1|2010-04-15|2013-01-31|Spirogen Developments Sàrl|Pyrrolobenzodiazepines and conjugates thereof|

---

EP2558127B1|2010-04-15|2022-01-19|Seagen Inc.|Targeted pyrrolobenzodiazepine conjugates|

---

AU2011239525B2|2010-04-15|2015-04-09|Medimmune Limited|Pyrrolobenzodiazepines used to treat proliferative diseases|

---

US20130058947A1|2011-09-02|2013-03-07|Stem Centrx, Inc|Novel Modulators and Methods of Use|

---

WO2013041606A1|2011-09-20|2013-03-28|Spirogen Sàrl|Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates|

---

WO2013053872A1|2011-10-14|2013-04-18|Spirogen Sàrl|Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines|

---

US9387259B2|2011-10-14|2016-07-12|Seattle Genetics, Inc.|Pyrrolobenzodiazepines and targeted conjugates|

---

EA027386B1|2011-10-14|2017-07-31|Медимьюн Лимитед|Pyrrolobenzodiazepines|

---

JP6393617B2|2011-10-14|2018-09-19|シアトル ジェネティクス，インコーポレーテッド|Pyrrolobenzodiazepine and target conjugates|

---

MX341523B|2011-10-14|2016-08-24|Medimmune Ltd|Pyrrolobenzodiazepines.|

---

CN103987407B|2011-10-14|2016-08-24|麦迪穆有限责任公司|Pyrrolobenzodiazepines Zhuo and conjugate thereof|

---

CN108383909B|2012-02-24|2021-08-24|艾伯维施特姆森特克斯有限责任公司|anti-SEZ 6 antibodies and methods of use|

---

AU2013203459B2|2012-02-24|2016-11-03|Abbvie Stemcentrx Llc|DLL3 modulators and methods of use|

---

US9321774B2|2012-04-30|2016-04-26|Medimmune Limited|Pyrrolobenzodiazepines|

---

ES2623042T3|2012-04-30|2017-07-10|Medimmune Limited|Pyrrolobenzodiazepines|

---

HUE039329T2|2012-10-12|2018-12-28|Adc Therapeutics Sa|Pyrrolobenzodiazepine-antibody conjugates|

---

WO2014057122A1|2012-10-12|2014-04-17|Adc Therapeutics Sàrl|Pyrrolobenzodiazepine-anti-cd22 antibody conjugates|

---

WO2014057074A1|2012-10-12|2014-04-17|Spirogen Sàrl|Pyrrolobenzodiazepines and conjugates thereof|

---

EP2906250B1|2012-10-12|2018-05-30|ADC Therapeutics SA|Pyrrolobenzodiazepine-anti-psma antibody conjugates|

---

SI2906298T1|2012-10-12|2018-12-31|Adc Therapeutics Sa|Pyrrolobenzodiazepine-antibody conjugates|

---

AU2013328619B2|2012-10-12|2016-11-17|Adc Therapeutics Sa|Pyrrolobenzodiazepine - anti-PSMA antibody conjugates|

---

ES2660029T3|2012-10-12|2018-03-20|Medimmune Limited|Antibody-pyrrolobenzodiazepine conjugates|

---

US9745303B2|2012-10-12|2017-08-29|Medimmune Limited|Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation|

---

AU2013328674B2|2012-10-12|2017-06-22|Medimmune Limited|Pyrrolobenzodiazepines and conjugates thereof|

---

ES2701076T3|2012-11-24|2019-02-20|Hangzhou Dac Biotech Co Ltd|Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells|

---

CN110452242A|2012-12-21|2019-11-15|麦迪穆有限责任公司|Pyrrolobenzodiazepines Zhuo and its conjugate|

---

WO2014096365A1|2012-12-21|2014-06-26|Spirogen Sàrl|Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases|

---

AU2014218730B2|2013-02-22|2018-12-13|Abbvie Stemcentrx Llc|Novel antibody conjugates and uses thereof|

---

US9821074B2|2013-03-13|2017-11-21|Genentech, Inc.|Pyrrolobenzodiazepines and conjugates thereof|

---

CA2905181C|2013-03-13|2020-06-02|Medimmune Limited|Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy|

---

CA2904044C|2013-03-13|2020-03-31|Medimmune Limited|Pyrrolobenzodiazepines and conjugates thereof|

---

KR20160046914A|2013-08-28|2016-04-29|스템센트알엑스 인코포레이티드|Novel sez6 modulators and methods of use|

---

KR20160044042A|2013-08-28|2016-04-22|스템센트알엑스 인코포레이티드|Site-specific antibody conjugation methods and compositions|

---

GB201317982D0|2013-10-11|2013-11-27|Spirogen Sarl|Pyrrolobenzodiazepines and conjugates thereof|

---

GB201317981D0|2013-10-11|2013-11-27|Spirogen Sarl|Pyrrolobenzodiazepines and conjugates thereof|

---

US9956299B2|2013-10-11|2018-05-01|Medimmune Limited|Pyrrolobenzodiazepine—antibody conjugates|

---

EP3054985B1|2013-10-11|2018-12-26|Medimmune Limited|Pyrrolobenzodiazepine-antibody conjugates|

---

WO2015052532A1|2013-10-11|2015-04-16|Spirogen Sàrl|Pyrrolobenzodiazepine-antibody conjugates|

---

EP3065776A4|2013-11-06|2017-04-19|AbbVie Stemcentrx LLC|Novel anti-claudin antibodies and methods of use|

---

EP3080607A4|2013-12-12|2017-07-12|AbbVie Stemcentrx LLC|Novel anti-dpep3 antibodies and methods of use|

---

PE20161209A1|2014-02-21|2016-11-10|Abbvie Stemcentrx Llc|CONJUGATES OF ANTI-DROSOPHILA SIMILAR ANTIBODIES TO DELTA 3AND DRUGS FOR USE IN THE TREATMENT OF MELANOMA|

---

EP3122757A4|2014-02-28|2018-02-07|Hangzhou Dac Biotech Co., Ltd|Charged linkers and their uses for conjugation|

---

GB201407816D0|2014-05-02|2014-06-18|King S College London|Pyrrolobenzodiazepine Compounds|

---

TW201617368A|2014-09-05|2016-05-16|史坦森特瑞斯公司|Novel anti-MFI2 antibodies and methods of use|

---

US10188746B2|2014-09-10|2019-01-29|Medimmune Limited|Pyrrolobenzodiazepines and conjugates thereof|

---

GB201416112D0|2014-09-12|2014-10-29|Medimmune Ltd|Pyrrolobenzodiazepines and conjugates thereof|

---

BR112017011111A2|2014-11-25|2017-12-26|Adc Therapeutics Sa|pyrrolobenzodiazepine-antibody conjugates|

---

PE20171185A1|2015-01-14|2017-08-22|Bristol-Myers Squibb Company|BENZODIAZEPINE DIMERS UNITED WITH HETEROARYLENE BRIDGES, CONJUGATES OF THESE, AND THEIR METHODS OF PREPARATION AND USE|

---

US9527871B2|2015-01-14|2016-12-27|Bristol-Myers Squibb Company|Benzodiazepine dimers, conjugates thereof, and methods of making and using|

---

GB201506411D0|2015-04-15|2015-05-27|Bergenbio As|Humanized anti-axl antibodies|

---

EA201792516A1|2015-06-23|2018-05-31|Бристол-Маерс Сквибб Компани|Macrocyclic dimers of benzodiazepine, their conjugates, preparation and use|

---

US9839687B2|2015-07-15|2017-12-12|Suzhou M-Conj Biotech Co., Ltd.|Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule|

---

GB201601431D0|2016-01-26|2016-03-09|Medimmune Ltd|Pyrrolobenzodiazepines|

---

GB201602359D0|2016-02-10|2016-03-23|Medimmune Ltd|Pyrrolobenzodiazepine Conjugates|

---

WO2017184942A1|2016-04-21|2017-10-26|Abbvie Stemcentrx Llc|Novel anti-bmpr1b antibodies and methods of use|

---

GB201607478D0|2016-04-29|2016-06-15|Medimmune Ltd|Pyrrolobenzodiazepine Conjugates|

---

US20200023072A1|2016-10-11|2020-01-23|Medimmune Limited|Antibody-drug conjugates with immune-mediated therapy agents|

---

GB201617466D0|2016-10-14|2016-11-30|Medimmune Ltd|Pyrrolobenzodiazepine conjugates|

---

EP3888691A1|2016-11-14|2021-10-06|Hangzhou Dac Biotech Co., Ltd.|Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers|

---

WO2018146189A1|2017-02-08|2018-08-16|Adc Therapeutics Sa|Pyrrolobenzodiazepine-antibody conjugates|

---

CA3058360A1|2017-03-29|2018-10-04|Legochem Biosciences, Inc.|Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same|

---

EP3612234A1|2017-04-20|2020-02-26|ADC Therapeutics SA|Combination therapy with an anti-axl antibody-drug conjugate|

---

KR102270107B1|2017-08-18|2021-06-30|메디뮨 리미티드|pyrrolobenzodiazepine conjugate|

---

US20200289660A1|2017-11-14|2020-09-17|Medimmune Limited|Pyrrolobenzodiazepine conjugates|

---

EP3801630A1|2018-05-25|2021-04-14|Medimmune Limited|Pyrrolobenzodiazepine conjugates|

---

GB201814281D0|2018-09-03|2018-10-17|Femtogenix Ltd|Cytotoxic agents|

---

EP3866857A1|2018-10-19|2021-08-25|MedImmune Limited|Pyrrolobenzodiazepine conjugates|

---

US20210380605A1|2018-10-19|2021-12-09|Medimmune Limited|Pyrrolobenzodiazepine conjugates|

---

KR20200084802A|2019-01-03|2020-07-13|주식회사 레고켐 바이오사이언스|Pyrrolobenzodiazepine dimer compounds with improved safety and its use|

---

KR20210086557A|2019-12-31|2021-07-08|주식회사 레고켐 바이오사이언스|Pyrrolobenzodiazepine derivatives and its ligand-linker conjugate|

法律状态:
2010-07-15| FGA| Letters patent sealed or granted (standard patent)|

---

2013-03-14| DA2| Applications for amendment section 104|Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO SPIROGEN SARL . |

---

2015-11-19| PC| Assignment registered|Owner name: MEDIMMUNE LIMITED Free format text: FORMER OWNER WAS: SPIROGEN SARL |

---

2021-06-10| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|

优先权:

---

申请号 | 申请日 | 专利标题

---

GB0226593.2||2002-11-14||

---

GBGB0226593.2A|GB0226593D0|2002-11-14|2002-11-14|Compounds|

---

PCT/GB2003/004963|WO2004043963A1|2002-11-14|2003-11-14|Pyrrolobenzodiazepines|

---